Installed Building Products Reports First Quarter 2026 Results; Declares Regular Quarterly Cash Dividend

Installed Building Products Reports First Quarter 2026 Results; Declares Regular Quarterly Cash Dividend

COLUMBUS, Ohio–(BUSINESS WIRE)–
Installed Building Products, Inc. (the “Company” or “IBP”) (NYSE: IBP), an industry-leading installer of insulation and complementary building products, today announced results for the first quarter ended March 31, 2026.

First Quarter 2026 Highlights (Comparisons are to Prior Year Period)

  • Net revenue decreased 3.5% to $660.5 million

    • Installation revenue decreased 5.8% to $609.8 million, including sales from IBP’s recent acquisitions

    • Other revenue, net of eliminations, which includes IBP’s manufacturing and distribution operations, increased 34.8% to $50.7 million

  • Net income decreased to $34.8 million

  • Adjusted EBITDA* decreased to $92.1 million

  • Net income per diluted share decreased to $1.29

  • Adjusted net income* was $48.4 million, or $1.79 per diluted share

  • Net cash flow from operations increased 11.1% to $102.3 million

  • At March 31, 2026, IBP had $474.3 million in cash and cash equivalents

  • Repurchased approximately 91 thousand shares of common stock at a total cost of approximately $25.4 million

  • Declared first quarter dividend of $0.39 per share that was paid to shareholders on March 31, 2026

Recent Developments

  • IBP’s Board of Directors declared the second quarter regular cash dividend of $0.39 per share, representing more than a 5% increase to the Company’s regular dividend in the prior year period

  • Effective May 6, 2026, Ryan Ricketts has been appointed Director of Investor Relations and Financial Planning, succeeding Darren Hicks, who will be departing the Company to pursue another opportunity

“We delivered solid top-line results amidst challenging regional weather conditions and a macroeconomic backdrop that has raised uncertainty with respect to U.S. consumer sentiment and new home sales activity. Throughout the quarter, we remained focused on meeting customers’ needs through maintaining elevated service quality while emphasizing product diversification and prudent expense management. Our commercial end market continued to show strength, delivering double-digit installation sales growth. Heavy commercial sales growth exceeded 20% and the commercial end market also benefited from light commercial acquisition revenue. While we expect near-term challenges within U.S. residential construction to continue, we remain intentional with our pursuit of growth and capital allocation decisions,” stated Jeff Edwards, Chairman and Chief Executive Officer.

“I also want to thank Darren, who has been a valued member of our team since joining IBP in March 2021,” continued Mr. Edwards. “Ryan, as Director of Financial Planning, has played an integral role in our financial planning and analysis function, and he is a natural fit to lead our investor relations efforts. I look forward to his contributions as we continue to execute on our strategy and engage with the investment community and wish Darren the best in his future endeavors.”

Acquisition Update

During the 2026 first quarter, IBP completed the following acquisitions, which added approximately $28 million of annual revenue:

Close

Date

 

Acquisition

Core

End Market (1)

Primary Product Category

Approximate

Annual Sales

Jan. 2026

Biomax Spray Foam Insulation, LLC

Res. + Com.

Insulation

$5 million

Feb. 2026

Thermo-Tech Mechanical Insulation, Inc.

Com. + Ind.

Mechanical Insulation

$13 million

Feb. 2026

Northstar Comfort Services

Res.

Insulation

$3 million

Mar. 2026

Waterproofing, Inc.

Res. + Com.

Waterproofing

$7 million

(1)

Res. – Residential end market, which includes single-family and multi-family. Com. – Commercial end market, which includes heavy and light commercial. Ind. – Industrial end market.

2026 Second Quarter Regular Cash Dividend

IBP’s Board of Directors has approved the Company’s quarterly cash dividend of $0.39 per share, payable on June 30, 2026, to stockholders of record on June 15, 2026. The second quarter regular cash dividend represents an over 5% increase from last year’s second quarter cash dividend payment.

Share Repurchases

During the three months ended March 31, 2026, IBP repurchased approximately 91 thousand shares of its common stock at a total cost of $25.4 million. At March 31, 2026, the Company had $474.6 million available under its stock repurchase program, which expires March 1, 2027.

First Quarter 2026 Results Overview

For the first quarter of 2026, net revenue was $660.5 million, a decrease of 3.5% from $684.8 million for the first quarter of 2025. On a consolidated same branch basis, net revenue decreased 5.9% from the prior year quarter. Residential same branch sales within the Company’s Installation segment were down 11.2% in the quarter while commercial same branch sales within the Installation segment were up 10.7% from the prior year quarter.

Our price/mix results were flat during the first quarter and job volumes were down 10.0% relative to the same period last year. It is important to note that the results of our heavy commercial end market and the Other segment results are not included in that price/mix and volume disclosure. Including the heavy commercial installation sales, but still excluding the Other segment results, price mix increased 2.9% while job volume was down 9.9% during the 2026 first quarter.

Gross profit decreased 5.1% to $212.3 million in the first quarter of 2026 from $223.7 million in the prior year quarter. As a percent of net revenue, gross profit was 32.1% and adjusted gross profit* was 32.2%, compared to 32.7% in the same period last year. Higher vehicle-related expense as a percent of net revenue served as a notable headwind to our first quarter of 2026 adjusted gross profit margin performance relative to the prior year period. Adjusted gross profit primarily adjusts for the Company’s share-based compensation expense.

Selling and administrative expense, as a percent of total revenue, was 21.8% in the first quarter of 2026 and 21.0% in the prior year period. Adjusted selling and administrative expense*, as a percent of net revenue, was 20.9% compared to 20.1% in the prior year quarter. Adjusted administrative expense as a percent of net revenue was impacted by higher medical and general liability insurance relative to the prior year.

Net income was $34.8 million, or $1.29 per diluted share, compared to $45.4 million, or $1.64 per diluted share in the prior year quarter. Net profit margin for the first quarter was 5.3% compared to 6.6% in the prior year quarter. Adjusted net income* was $48.4 million, or $1.79 per diluted share, compared to $57.6 million, or $2.08 per diluted share in the prior year quarter. Adjusted net profit margin* for the first quarter was 7.3% compared to 8.4% in the prior year quarter. Adjusted net income accounts for the impact of non-core items in both periods, including an addback for non-cash amortization expense related to acquisitions.

EBITDA* in the first quarter of 2026 was $85.4 million, an 11.0% decrease from $96.0 million in the prior year quarter. Adjusted EBITDA* was $92.1 million, a 10.1% decrease from the prior year quarter representing an adjusted EBITDA margin* of 13.9%. In the prior year quarter, adjusted EBITDA* was $102.4 million, representing an adjusted EBITDA margin* of 15.0%.

Conference Call and Webcast

The Company will host a conference call and webcast on May 7, 2026 at 10:00 a.m. Eastern Time to discuss these results. To participate in the call, please dial 877-407-0792 (domestic) or 201-689-8263 (international). The live webcast will be available at www.installedbuildingproducts.com in the investor relations section. A replay of the conference call will be available through May 21, 2026 by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and entering the passcode 13759110.

Alternatively, participants can register for the call 15 minutes prior to the event by using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

About Installed Building Products

Installed Building Products, Inc. is one of the nation’s largest new residential insulation installers and is a diversified installer of complementary building products, including waterproofing, fire-stopping, fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving and mirrors and other products for residential and commercial builders located in the continental United States. The Company manages all aspects of the installation process for its customers, from direct purchase and receipt of materials from national manufacturers to its timely supply of materials to job sites and quality installation. The Company offers its portfolio of services for new and existing single-family and multi-family residential and commercial building projects in all 48 continental states and the District of Columbia from its national network of over 250 branch locations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including with respect to the housing market and the commercial market, our operations, industry and economic conditions, our financial and business model, payment of dividends, the demand for our services and product offerings, expansion of our national footprint and end markets, diversification of our products, our ability to grow and strengthen our market position, our ability to pursue and integrate value-enhancing acquisitions and the expected amount of acquired revenue, our ability to improve sales and profitability, and expectations for demand for our services and our earnings. Forward-looking statements may generally be identified by the use of words such as “anticipate,” “believe,” “expect,” “intends,” “plan,” and “will” or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Any forward-looking statements that we make herein and in any future reports and statements are not guarantees of future performance, and actual results may differ materially from those expressed in or suggested by such forward-looking statements as a result of various factors, including, without limitation, general economic and industry conditions; increases in mortgage interest rates and rising home prices; inflation and interest rates; the material price and supply environment; increased tariffs; federal government shutdowns and uncertainty regarding the federal government’s policy changes; geopolitical conflicts; the timing of increases in our selling prices; the risk that the Company may reduce, suspend or eliminate dividend payments in the future; and the factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as the same may be updated from time to time in our subsequent filings with the Securities and Exchange Commission. In addition, any future declaration of dividends will be subject to the final determination of our Board of Directors. Any forward-looking statement made by the Company in this press release speaks only as of the date hereof. New risks and uncertainties arise from time to time, and it is impossible for the Company to predict these events or how they may affect it. The Company has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws.

*Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release contains the non-GAAP financial measures of EBITDA, Adjusted EBITDA, Adjusted EBITDA margin (i.e., Adjusted EBITDA divided by net revenue), Adjusted Net Income, Adjusted Net Income per diluted share, Adjusted Gross Profit and Adjusted Selling and Administrative expense. The reasons for the use of these measures, reconciliations of EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Net Income per diluted share, Adjusted Gross Profit, and Adjusted Selling and Administrative expense to the most directly comparable GAAP measures and other information relating to these measures are included below following the unaudited condensed consolidated financial statements. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for IBP’s financial results prepared in accordance with GAAP.

INSTALLED BUILDING PRODUCTS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(unaudited, in millions, except share and per share amounts)

 

 

Three months ended March 31,

 

 

2026

 

 

2025

 

Net revenue

$

660.5

 

$

684.8

 

Cost of sales

 

448.2

 

 

461.1

 

Gross profit

 

212.3

 

 

223.7

 

Operating expenses

 

 

 

Selling

 

34.0

 

 

35.4

 

Administrative

 

110.2

 

 

108.4

 

Amortization

 

10.5

 

 

10.1

 

Operating income

 

57.6

 

 

69.8

 

Other expense, net

 

 

 

Interest expense, net

 

10.3

 

 

8.3

 

Other expense

 

0.2

 

 

0.2

 

Income before income taxes

 

47.1

 

 

61.3

 

Income tax provision

 

12.3

 

 

15.9

 

Net income

$

34.8

 

$

45.4

 

Other comprehensive income (loss), net of tax:

 

 

 

Net change on cash flow hedges, net of tax (provision) benefit of ($0.1) and $1.8 for the three months ended March 31, 2026 and 2025, respectively.

 

0.3

 

 

(5.3

)

Comprehensive income

$

35.1

 

$

40.1

 

Earnings Per Share:

 

 

 

Basic

$

1.30

 

$

1.65

 

Diluted

$

1.29

 

$

1.64

 

Weighted average shares outstanding:

 

 

 

Basic

 

26,798,598

 

 

27,517,419

 

Diluted

 

26,965,335

 

 

27,695,912

 

 

 

 

 

Cash dividends declared per share

$

2.19

 

$

2.07

 

INSTALLED BUILDING PRODUCTS, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited, in millions, except share and per share amounts)

 

 

March 31,

 

December 31,

 

 

2026

 

 

 

2025

 

ASSETS

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

474.3

 

 

$

321.9

 

Accounts receivable (less allowance for credit losses of $14.6 and $13.9 at March 31, 2026 and December 31, 2025, respectively)

 

426.4

 

 

 

444.1

 

Inventories

 

205.7

 

 

 

203.0

 

Prepaid expenses and other current assets

 

63.7

 

 

 

73.6

 

Total current assets

 

1,170.1

 

 

 

1,042.6

 

Property and equipment, net

 

191.0

 

 

 

183.3

 

Operating lease right-of-use assets

 

99.2

 

 

 

98.7

 

Goodwill

 

460.8

 

 

 

450.4

 

Customer relationships, net

 

175.1

 

 

 

172.2

 

Other intangibles, net

 

91.4

 

 

 

89.3

 

Other non-current assets

 

42.2

 

 

 

31.5

 

Total assets

$

2,229.8

 

 

$

2,068.0

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities

 

 

 

Current maturities of long-term debt

$

35.6

 

 

$

36.6

 

Current maturities of operating lease obligations

 

38.1

 

 

 

37.0

 

Current maturities of finance lease obligations

 

3.6

 

 

 

2.7

 

Accounts payable

 

124.9

 

 

 

119.0

 

Accrued compensation

 

55.0

 

 

 

69.5

 

Other current liabilities

 

92.6

 

 

 

79.4

 

Total current liabilities

 

349.8

 

 

 

344.2

 

Long-term debt

 

1,035.4

 

 

 

850.0

 

Operating lease obligations

 

60.9

 

 

 

61.4

 

Finance lease obligations

 

7.0

 

 

 

4.0

 

Deferred income taxes

 

24.5

 

 

 

24.7

 

Other long-term liabilities

 

84.7

 

 

 

73.8

 

Total liabilities

 

1,562.3

 

 

 

1,358.1

 

Commitments and contingencies

 

 

 

Stockholders’ equity

 

 

 

Preferred Stock; $0.01 par value: 5,000,000 authorized and 0 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

 

 

 

 

 

Common stock; $0.01 par value: 100,000,000 authorized, 33,891,774 and 33,837,379 issued and 26,938,128 and 26,975,227 shares outstanding at March 31, 2026 and December 31, 2025, respectively

 

0.3

 

 

 

0.3

 

Additional paid in capital

 

291.3

 

 

 

284.1

 

Retained earnings

 

1,019.0

 

 

 

1,043.4

 

Treasury stock; at cost: 6,953,646 and 6,862,152 shares at March 31, 2026 and December 31, 2025, respectively

 

(665.5

)

 

 

(640.0

)

Accumulated other comprehensive income

 

22.4

 

 

 

22.1

 

Total stockholders’ equity

 

667.5

 

 

 

709.9

 

Total liabilities and stockholders’ equity

$

2,229.8

 

 

$

2,068.0

 

INSTALLED BUILDING PRODUCTS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in millions)

 

 

Three months ended March 31,

 

 

2026

 

 

 

2025

 

Cash flows from operating activities

 

 

 

Net income

$

34.8

 

 

$

45.4

 

Adjustments to reconcile net income to net cash provided by operating activities

 

 

 

Depreciation and amortization of property and equipment

 

17.5

 

 

 

16.3

 

Amortization of operating lease right-of-use assets

 

9.7

 

 

 

8.8

 

Amortization of intangibles

 

10.5

 

 

 

10.1

 

Amortization of deferred financing costs and debt discount

 

0.5

 

 

 

0.4

 

Provision for credit losses

 

1.7

 

 

 

2.1

 

Write-off of debt issuance costs

 

1.2

 

 

 

 

Gain on sale of property and equipment

 

(0.3

)

 

 

(0.2

)

Non-cash stock compensation

 

5.7

 

 

 

5.9

 

Other, net

 

(1.7

)

 

 

(2.4

)

Changes in assets and liabilities, excluding effects of acquisitions

 

 

 

Accounts receivable

 

19.4

 

 

 

12.4

 

Inventories

 

(2.1

)

 

 

(3.4

)

Other assets

 

2.7

 

 

 

11.4

 

Accounts payable

 

4.1

 

 

 

(1.6

)

Income taxes receivable/payable

 

12.9

 

 

 

11.6

 

Other liabilities

 

(14.3

)

 

 

(24.7

)

Net cash provided by operating activities

 

102.3

 

 

 

92.1

 

Cash flows from investing activities

 

 

 

Purchases of property and equipment

 

(16.6

)

 

 

(20.2

)

Acquisitions of businesses, net of cash acquired of $- in 2026 and 2025, respectively

 

(28.8

)

 

 

(8.3

)

Proceeds from sale of property and equipment

 

0.5

 

 

 

0.4

 

Settlements with interest rate swap counterparties

 

 

 

 

3.4

 

Other

 

(0.4

)

 

 

(1.4

)

Net cash used in investing activities

$

(45.3

)

 

$

(26.1

)

 

Three months ended March 31,

 

 

2026

 

 

 

2025

 

Cash flows from financing activities

 

 

 

Proceeds from Senior Notes

$

500.0

 

 

$

 

Payments on Senior Notes

 

(300.0

)

 

 

 

Payments on Term Loan

 

(1.3

)

 

 

(1.3

)

Proceeds from vehicle and equipment notes payable

 

 

 

 

5.8

 

Debt issuance costs

 

(9.0

)

 

 

 

Principal payments on long-term debt

 

(8.3

)

 

 

(7.2

)

Principal payments on finance lease obligations

 

(1.1

)

 

 

(0.7

)

Dividends paid

 

(58.7

)

 

 

(56.8

)

Acquisition-related obligations

 

(0.7

)

 

 

(0.4

)

Repurchase of common stock

 

(25.4

)

 

 

(34.3

)

Surrender of common stock awards by employees

 

(0.1

)

 

 

 

Net cash provided by (used in) financing activities

 

95.4

 

 

 

(94.9

)

Net change in cash and cash equivalents

 

152.4

 

 

 

(28.9

)

Cash and cash equivalents at beginning of period

 

321.9

 

 

 

327.6

 

Cash and cash equivalents at end of period

$

474.3

 

 

$

298.7

 

Supplemental disclosures of cash flow information

 

 

 

Net cash paid during the period for:

 

 

 

Interest

$

16.4

 

 

$

14.7

 

Income taxes, net of refunds

 

(0.6

)

 

 

0.7

 

Supplemental disclosures of non-cash activities

 

 

 

Right-of-use assets obtained in exchange for operating lease obligations

$

10.2

 

 

$

10.2

 

Property and equipment obtained in exchange for finance lease obligations

 

5.0

 

 

 

0.2

 

Seller obligations in connection with acquisition of businesses

 

3.0

 

 

 

0.6

 

Unpaid purchases of property and equipment included in accounts payable

 

2.3

 

 

 

3.0

 

INSTALLED BUILDING PRODUCTS, INC.

SEGMENT INFORMATION

(unaudited, in millions)

 

Information on Segments

 

Our Company has three operating segments consisting of Installation, Distribution and Manufacturing. The Other category reported below reflects the operations of our Distribution and Manufacturing operating segments. The following tables represent our segment information for the three months ended March 31, 2026 and 2025 (in millions):

 

 

Three months ended March 31,

Installation Segment

 

2026

 

 

 

2025

 

Revenue

$

609.8

 

 

$

647.2

 

Cost of sales (1)

 

393.5

 

 

 

417.7

 

Segment gross profit

$

216.3

 

 

$

229.5

 

Segment gross profit percentage

 

35.5

%

 

 

35.5

%

(1)

Cost of sales included in the Installation segment gross profit is exclusive of depreciation and amortization for the three months ended March 31, 2026 and 2025.

The reconciliation of Installation revenue and segment gross profit for each period as shown in the table above to consolidated net revenue and income before income taxes is as follows (in millions):

 

 

Three months ended March 31,

 

 

2026

 

 

 

2025

 

Reconciliation of revenue:

 

 

 

Installation segment revenue

$

609.8

 

 

$

647.2

 

Other revenue (1)

 

68.4

 

 

 

43.9

 

Elimination of inter-segment revenue

 

(17.7

)

 

 

(6.3

)

Total consolidated net revenue

$

660.5

 

 

$

684.8

 

Reconciliation of segment gross profit:

 

 

 

Installation segment gross profit

$

216.3

 

 

$

229.5

 

Other gross profit (1)

 

17.7

 

 

 

11.3

 

Elimination of inter-segment gross profit

 

(5.4

)

 

 

(1.9

)

Less:

 

 

 

Depreciation and amortization

 

16.3

 

 

 

15.2

 

Total consolidated gross profit, as reported

 

212.3

 

 

 

223.7

 

Operating expenses

 

154.7

 

 

 

153.9

 

Operating income

 

57.6

 

 

 

69.8

 

Other expense, net

 

10.5

 

 

 

8.5

 

Income before income taxes

$

47.1

 

 

$

61.3

 

(1)

Other revenue and other gross profit include the remaining two operating segments, Distribution and Manufacturing before inter-segment eliminations. These operating segments are each below the quantitative thresholds for being reported as a reportable segment for the three months ended March 31, 2026 and 2025.

INSTALLED BUILDING PRODUCTS, INC.

REVENUE BY END MARKET

(unaudited, in millions)

 

 

Three months ended March 31,

 

2026

 

2025

Installation

 

 

 

 

 

 

 

Residential new construction

$

443.3

 

67

%

 

$

494.4

 

72

%

Repair and remodel

 

41.1

 

6

%

 

 

42.4

 

6

%

Commercial

 

125.4

 

19

%

 

 

110.4

 

17

%

Net revenues – Installation

$

609.8

 

92

%

 

$

647.2

 

95

%

Other

 

50.7

 

8

%

 

 

37.6

 

5

%

Net revenue, as reported

$

660.5

 

100

%

 

$

684.8

 

100

%

Reconciliation of Non-GAAP Financial Measures

EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income, Adjusted Gross Profit and Adjusted Selling and Administrative Expense measure performance by adjusting GAAP net income, EBITDA, gross profit and selling and administrative expense, respectively, for certain income or expense items that are not considered part of our core operations. We believe that the presentation of these measures provides useful information to investors regarding our results of operations because it assists both investors and us in analyzing and benchmarking the performance and value of our business.

We believe the Adjusted EBITDA measure is useful to investors and us as a measure of comparative operating performance from period to period as it measures our changes in pricing decisions, cost controls and other factors that impact operating performance, and removes the effect of our capital structure (primarily interest expense), asset base (primarily depreciation and amortization), items outside our control (primarily income taxes) and the volatility related to the timing and extent of other activities such as asset impairments and non-core income and expenses. Accordingly, we believe that this measure is useful for comparing general operating performance from period to period. In addition, we use various EBITDA-based measures in determining the achievement of awards under certain of our incentive compensation programs. Other companies may define Adjusted EBITDA differently and, as a result, our measure may not be directly comparable to measures of other companies. In addition, Adjusted EBITDA may be defined differently for purposes of covenants contained in our revolving credit facility or any future facility.

Although we use the Adjusted EBITDA measure to assess the performance of our business, the use of the measure is limited because it does not include certain material expenses, such as interest and taxes, necessary to operate our business. Adjusted EBITDA should be considered in addition to, and not as a substitute for, GAAP net income as a measure of performance. Our presentation of this measure should not be construed as an indication that our future results will be unaffected by unusual or non-recurring items. This measure has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Because of these limitations, this measure is not intended as an alternative to net income as an indicator of our operating performance, as an alternative to any other measure of performance in conformity with GAAP or as an alternative to cash flow provided by operating activities as a measure of liquidity. You should therefore not place undue reliance on this measure or ratios calculated using this measure.

We also believe the Adjusted Net Income measure is useful to investors and us as a measure of comparative operating performance from period to period as it measures our changes in pricing decisions, cost controls and other factors that impact operating performance, and removes the effect of certain non-core items such as discontinued operations, acquisition related expenses, amortization expense, the tax impact of these certain non-core items, and the volatility related to the timing and extent of other activities such as asset impairments and non-core income and expenses. To make the financial presentation more consistent with other public building products companies, beginning in the fourth quarter 2016 we included an addback for non-cash amortization expense related to acquisitions. Accordingly, we believe that this measure is useful for comparing general operating performance from period to period. Other companies may define Adjusted Net Income differently and, as a result, our measure may not be directly comparable to measures of other companies. In addition, Adjusted Net Income may be defined differently for purposes of covenants contained in our revolving credit facility or any future facility.

INSTALLED BUILDING PRODUCTS, INC.

RECONCILIATION OF GAAP TO NON-GAAP MEASURES

ADJUSTED NET INCOME CALCULATIONS

(unaudited, in millions, except share and per share amounts)

 

The tables below reconcile Adjusted Net Income to the most directly comparable GAAP financial measure, net income, for the periods presented therein. We have included Adjusted Net Income in this press release because it is a key measure used by our management team to understand the operating performance and profitability of our business.

 

Per share figures may reflect rounding adjustments and consequently totals may not appear to sum.

 

 

 

Three months ended March 31,

 

 

 

2026

 

 

 

2025

 

Net income, as reported

 

$

34.8

 

 

$

45.4

 

Adjustments for adjusted net income

 

 

 

 

Share-based compensation expense

 

5.7

 

 

 

5.9

 

Acquisition related expenses

 

1.0

 

 

 

0.5

 

Amortization expense (1)

 

 

10.5

 

 

 

10.1

 

Loan refinancing expenses (2)

 

 

1.2

 

 

 

 

Tax impact of adjusted items at a normalized tax rate (3)

 

 

(4.8

)

 

 

(4.3

)

Adjusted net income

 

$

48.4

 

 

$

57.6

 

Weighted average shares outstanding (diluted)

 

 

26,965,335

 

 

 

27,695,912

 

Diluted net income per share, as reported

 

$

1.29

 

 

$

1.64

 

Adjustments for diluted adjusted net income, net of tax impact, per share (4)

 

 

0.50

 

 

 

0.44

 

Diluted adjusted net income per share

 

$

1.79

 

 

$

2.08

(1)

Addback of all non-cash amortization resulting from business combinations.

 

(2)

Includes $1.2 million of non-cash write-off of capitalized loan expense in connection with loan refinancing for the three months ended March 31, 2026.

 

(3)

Normalized effective tax rate of 26.0% applied to periods presented.

 

(4)

Includes adjustments related to the items noted above, net of tax.

INSTALLED BUILDING PRODUCTS, INC.

RECONCILIATION OF GAAP TO NON-GAAP MEASURES

ADJUSTED GROSS PROFIT CALCULATIONS

(unaudited, in millions)

 

The table below reconciles Adjusted Gross Profit to the most directly comparable GAAP financial measure, gross profit, for the periods presented therein.

 

 

 

Three months ended March 31,

 

 

 

2026

 

 

 

2025

 

Gross profit

 

$

212.3

 

 

$

223.7

 

Share-based compensation expense

 

 

0.3

 

 

 

0.3

 

Adjusted gross profit

 

$

212.6

 

 

$

224.0

 

 

 

 

 

 

Gross profit margin

 

 

32.1

%

 

 

32.7

%

Adjusted gross profit margin

 

 

32.2

%

 

 

32.7

%

INSTALLED BUILDING PRODUCTS, INC.

RECONCILIATION OF GAAP TO NON-GAAP MEASURES

ADJUSTED SELLING AND ADMINISTRATIVE EXPENSE CALCULATIONS

(unaudited, in millions)

 

The table below reconciles Adjusted Selling and Administrative to the most directly comparable GAAP financial measure, selling and administrative, for the periods presented therein.

 

 

Three months ended March 31,

 

 

 

2026

 

 

 

2025

 

Selling expense

 

$

34.0

 

 

$

35.4

 

Administrative expense

 

 

110.2

 

 

 

108.4

 

Selling and Administrative expense, as reported

 

 

144.2

 

 

 

143.8

 

Share-based compensation expense

 

 

5.4

 

 

 

5.6

 

Acquisition related expenses

 

 

1.0

 

 

 

0.5

 

Adjusted Selling and Administrative expense

 

$

137.8

 

 

$

137.7

 

 

 

 

 

 

Selling and Administrative expense – % Net revenue

 

 

21.8

%

 

 

21.0

%

Adjusted Selling and Administrative expense – % Net revenue

 

 

20.9

%

 

 

20.1

%

INSTALLED BUILDING PRODUCTS, INC.

RECONCILIATION OF GAAP TO NON-GAAP MEASURES

EBITDA AND ADJUSTED EBITDA CALCULATIONS

(unaudited, in millions)

The tables below reconcile EBITDA and Adjusted EBITDA to the most directly comparable GAAP financial measure, net income, for the periods presented therein.

 

 

Three months ended March 31,

 

 

 

2026

 

 

 

2025

 

Net income, as reported

 

$

34.8

 

 

$

45.4

 

Interest expense

 

 

10.3

 

 

 

8.3

 

Provision for income tax

 

 

12.3

 

 

 

15.9

 

Depreciation and amortization

 

 

28.0

 

 

 

26.4

 

EBITDA

 

 

85.4

 

 

 

96.0

 

Acquisition related expenses

 

 

1.0

 

 

 

0.5

 

Share-based compensation expense

 

 

5.7

 

 

 

5.9

 

Adjusted EBITDA

 

$

92.1

 

 

$

102.4

 

 

 

 

 

 

Net profit margin

 

 

5.3

%

 

 

6.6

%

EBITDA margin

 

 

12.9

%

 

 

14.0

%

Adjusted EBITDA margin

 

 

13.9

%

 

 

15.0

%

INSTALLED BUILDING PRODUCTS, INC.

SUPPLEMENTARY TABLE

(unaudited)

 

 

 

Three months ended March 31,

 

 

2026

 

2025

Period-over-period Growth

 

 

 

 

Consolidated Sales Growth

 

(3.5

)%

 

(1.2

)%

Consolidated Same Branch Sales Growth(1)

 

(5.9

)%

 

(4.2

)%

 

 

 

 

 

Installation Segment Sales Growth

 

 

 

 

Sales Growth(2)

 

(5.8

)%

 

(1.3

)%

Residential Sales Growth(3)

 

(10.3

)%

 

(1.7

)%

Single-Family Sales Growth(4)

 

(10.1

)%

 

(1.0

)%

Multi-Family Sales Growth(5)

 

(11.0

)%

 

(4.2

)%

Commercial Sales Growth(6)

 

13.6

%

 

(2.3

)%

 

 

 

 

 

Installation Segment Same Branch Sales Growth(1)

 

 

 

 

Same Branch Sales Growth(2)

 

(7.0

)%

 

(3.7

)%

Volume Growth, Including Heavy Commercial(7)(8)(11)

 

(9.9

)%

 

(6.0

)%

Price/Mix Growth, Including Heavy Commercial(7)(9)(11)

 

2.9

%

 

2.3

%

Volume Growth, Excluding Heavy Commercial(7)(8)(11)

 

(10.0

)%

 

(5.6

)%

Price/Mix Growth, Excluding Heavy Commercial(7)(9)(11)

 

(0.1

)%

 

1.5

%

Residential Same Branch Sales Growth(3)

 

(11.2

)%

 

(4.6

)%

Single-Family Same Branch Sales Growth(4)

 

(11.3

)%

 

(4.5

)%

Multi-Family Same Branch Sales Growth(5)

 

(11.2

)%

 

(5.0

)%

Commercial Same Branch Sales Growth(6)

 

10.7

%

 

(2.8

)%

 

 

 

 

 

Other Sales Growth (Net of Eliminations)

 

 

 

 

Sales Growth (10)(11)

 

34.8

%

 

1.6

%

Same Branch Sales Growth (1)(10)(11)

 

13.6

%

 

(12.7

)%

 

 

 

 

 

U.S. Housing Market Growth (12)

 

 

 

 

Total Completions Growth

 

(13.6

)%

 

1.3

%

Single-Family Completions Growth

 

(12.3

)%

 

4.6

%

Multi-Family Completions Growth

 

(16.7

)%

 

(4.2

)%

(1)

Same-branch basis represents period-over-period change in sales for branch locations owned greater than 12 months as of each financial statement date.

(2)

Calculated based on period-over-period change in sales of all end markets for our Installation segment,.

(3)

Calculated based on period-over-period change in sales in the residential new construction end market for our Installation segment.

(4)

Calculated based on period-over-period change in sales in the single-family subset of the residential new construction end market for our Installation segment,

(5)

Calculated based on period-over-period change in sales in the multi-family subset of the residential new construction end market for our Installation segment,

(6)

Calculated based on period-over-period change in sales in the total commercial end market for our Installation segment, Our commercial end market consists of heavy and light commercial projects.

(7)

The heavy commercial end market, a subset of our total commercial end market, comprises projects that are much larger than our average installation job. As such, per-job revenue is much larger than the average job in all other end markets.

(8)

Calculated as period-over-period change in the number of completed same-branch jobs within our Installation segment for all markets.

(9)

Defined as change in the mix of products sold and related pricing changes and calculated as the change in period-over-period average selling price per same-branch jobs within our Installation segment for all markets we serve, multiplied by total current year jobs. The mix of end customer and product would have an impact on the year-over-year price per job.

(10)

Calculated based on period-over-period gross sales change, excluding intercompany transactions, in our Other category which consists of our Manufacturing and Distribution operating segments.

(11)

We revised this calculation to exclude certain intercompany sales. Percentages in all periods presented conform to this

revised method.

(12)

U.S. Census Bureau data, as revised.

INSTALLED BUILDING PRODUCTS, INC.

INCREMENTAL REVENUE AND ADJUSTED EBITDA MARGINS

(unaudited, in millions)

Revenue Increase

 

 

Three months ended March 31,

 

 

 

2026

 

 

% Total

 

 

2025

 

 

% Total

Same Branch

 

$

(40.1

)

 

NMF

 

$

(29.0

)

 

NMF

Acquired

 

 

15.8

 

 

NMF

 

 

21.0

 

 

NMF

Total

 

$

(24.3

)

 

100.0

%

 

$

(8.0

)

 

100.0

%

Adjusted EBITDA Margin Contributions

 

 

Three months ended March 31,

 

 

 

2026

 

 

% Margin

 

 

2025

 

 

% Margin

Same Branch (1)

 

$

(12.3

)

 

(30.7

)%

 

$

(18.2

)

 

(62.8

)%

Acquired

 

 

2.0

 

 

12.7

%

 

 

3.4

 

 

16.2

%

Total

 

$

(10.3

)

 

(42.4

)%

 

$

(14.8

)

 

NMF

(1)

Same branch adjusted EBITDA margin contribution percentage is a percentage of same branch revenue increase.

 

The negative same branch % margin result reflects a decremental margin. NMF – Not meaningful figure.

 

Investor Relations:

614-221-9944

[email protected]

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Building Systems Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

Logo
Logo

BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center, a renowned cancer center in New York City, as a clinical trial site in its ongoing pivotal Phase 3 clinical study (Bria-ABC).

BriaCell has enjoyed a marked uptick in interest from premier cancer centers and patient enrollment numbers following the prominent independent feature of its Phase 3 clinical trial in Nature Medicine’s publication, “Eleven clinical trials that will shape medicine in 2026”, linked here.

BriaCell’s pivotal Phase 3 clinical study in Advanced Breast Cancer (Bria-ABC) is evaluating BriaCell’s lead clinical candidate, Bria-IMT™, plus an immune check point inhibitor versus treatment of physician’s choice in advanced metastatic breast cancer.

“At NYU Langone Health’s Perlmutter Cancer Center, we are dedicated to offering state-of-the-art treatments to patients with difficult-to-treat cancers,” stated Nancy Chan MD, Director, Breast Cancer Clinical Research, NYU Langone Health’s Perlmutter Cancer Center. “We look forward to helping accelerate the development of Bria-IMT, a novel immunotherapy with the potential to improve outcomes for patients with advanced metastatic breast cancer.”

“We are thrilled to partner with clinical experts at the renowned NYU Langone Health’s Perlmutter Cancer Center, a patient-focused, NCI-designated Comprehensive Cancer Center, to further expand patient access to our novel immunotherapy treatment,” said Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We continue to advance the study and look forward to sharing interim data in the coming months.”

Interim analysis of the pivotal Phase 3 study will be conducted after 144 patient events (deaths) have occurred, with overall survival (OS) as the primary endpoint. The study compares the Bria-IMT combination regimen with immune checkpoint inhibitor versus physician’s choice in patients with advanced metastatic breast cancer. Importantly, the Bria-IMT combination regimen has been granted FDA Fast Track designation, underscoring its potential to address a serious unmet medical need.

For additional information on BriaCell’s pivotal Phase 3 study, please visit ClinicalTrials.gov NCT06072612.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the addition of a new clinical site in the ongoing pivotal Phase 3 clinical study of Bria‑IMT, and expectations regarding patient enrollment, interim analysis timing and the potential clinical benefits of the Bria‑IMT combination regimen, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:

William V. Williams, MD
President & CEO
1-888-485-6340
[email protected]

Investor Relations Contact:

[email protected]



ARKO Corp. Reports First Quarter 2026 Results

RICHMOND, Va., May 07, 2026 (GLOBE NEWSWIRE) — ARKO Corp. (Nasdaq: ARKO) (“ARKO” or the “Company”), a Fortune 500 company and one of the largest operators of convenience stores and wholesalers of fuel in the United States, today announced financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Key Highlights (vs. Year-Ago Period)
1,2

  • Net loss for the quarter was $5.6 million compared to a net loss of $12.7 million.
  • Adjusted EBITDA for the quarter increased 65.1% to $50.9 million compared to $30.9 million.
  • Same-store merchandise sales excluding cigarettes increased approximately 0.4%, representing the strongest ex-cigarette performance in two years.
  • Merchandise margin for the quarter increased to 33.9% compared to 33.2%.
  • Retail same store fuel margin for the quarter increased to 48.0 cents per gallon compared to 38.7 cents per gallon, while same store fuel contribution increased approximately 20.1%.

Other Key Highlights

  • The Company’s subsidiary, ARKO Petroleum Corp. (Nasdaq: APC), completed an initial public offering (the “APC IPO”) of shares of its Class A common stock for total net proceeds of approximately $206.8 million (including proceeds from the underwriters’ exercise of their over-allotment option). The Company owns 35 million APC shares (73.6% of the economic interests in APC), representing an implied value of approximately $650 million, with an APC market capitalization of approximately $900 million as of May 5, 2026.
  • The Company applied $206.7 million of proceeds from the APC IPO to reduce debt during the quarter, reflecting the financial flexibility created by the APC IPO and ARKO’s disciplined capital allocation framework.
  • As part of the Company’s ongoing transformation plan, the Company converted 41 retail stores to dealer locations during the first quarter, bringing total conversions since program inception in 2024 to 450 sites. The Company has approximately 75 additional sites committed either under letter of intent, under contract or already converted since quarter end. The Company expects to complete these conversions, along with additional conversions, by the end of 2026. The Company continues to expect that, at scale, its channel optimization will deliver a cumulative annualized operating income benefit of more than $20 million, before general and administrative expense savings. In addition, the Company has identified more than $10 million in expected cumulative general and administrative expense savings with an opportunity for upside as the Company continues to execute the site conversion strategy in 2026. 
  • The Company opened two new-to-industry (“NTI”) retail stores and one NTI cardlock location during the first quarter, remains on track for three new Dunkin’ stores and one NTI retail store in 2026, continues to target 20 NTI cardlock openings in 2026, and continues to plan for approximately 25 remodels.
  • The Company relaunched its loyalty app on a new technology platform during the quarter and continues to advance customer engagement initiatives, including Fueling America’s Future, fas REWARDS, the $10 enrollment campaign, and 100 Days of Summer.
  • The Board of Directors declared a quarterly dividend of $0.03 per share of common stock to be paid on May 29, 2026 to stockholders of record as of May 18, 2026.

1 See Use of Non-GAAP Measures below.
2 All figures for fuel costs, fuel contribution and fuel margin per gallon exclude the fixed margin or fixed fee paid to the GPMP segment for the cost of fuel.

“Our first quarter results reflect both strong execution and the structural progress we have been making across the business,” said Arie Kotler, Chairman, President and Chief Executive Officer of ARKO. “Adjusted EBITDA increased approximately 65% year-over-year, same-store merchandise sales excluding cigarettes returned to growth, and same-store fuel gallon performance was the strongest we have seen in two years. While weather disruptions negatively affected January and early February results, trends improved as the quarter progressed, and March performance was particularly strong. We believe these results reflect the work we have been doing across dealerization, loyalty, fuel pricing, merchandising and cost discipline, while also demonstrating our ability to deliver value in a consumer environment that remains economically pressured and value-focused.”

Mr. Kotler continued: “With APC now public, investors have greater transparency into our wholesale, fleet fueling and GPMP businesses, and we believe the APC structure enhances financial flexibility and highlights the value embedded across our portfolio. As we move through 2026, we remain focused on disciplined capital allocation, continued dealerization, high-return growth opportunities such as cardlocks and retail NTIs, and building long-term value through consistent execution across all segments.”

First Quarter 2026 Segment Highlights


Retail

  For the Three Months

Ended March 31,
 
  2026     2025  
  (in thousands)  
Fuel gallons sold   194,737       225,063  
Same store fuel gallons sold decrease (%)1   (3.2%)       (6.2%)  
Fuel contribution2 $ 93,266     $ 85,273  
Fuel margin, cents per gallon3   47.9       37.9  
Same store fuel contribution1, 2 $ 91,303     $ 76,024  
Same store merchandise sales decrease (%)1   (0.5%)       (6.9%)  
Same store merchandise sales excluding
cigarettes increase (decrease) (%)1
  0.4%       (5.2%)  
Merchandise revenue $ 305,410     $ 354,485  
Merchandise contribution4 $ 103,510     $ 117,570  
Merchandise margin5   33.9%       33.2%  
Same store merchandise contribution1, 4 $ 101,228     $ 101,782  
Same store site operating expenses1 $ 150,884     $ 146,118  
           
1Same store is a common metric used in the convenience store industry. The Company considers a store a same store beginning in the first quarter in which the store had a full quarter of activity in the prior year. Refer toUse of Non-GAAP Measuresbelow for discussion of this measure.  
2Calculated as fuel revenue less fuel costs; excludes the fixed margin or fixed fee paid to the GPMP segment for the cost of fuel.  
3Calculated as fuel contribution divided by fuel gallons sold.  
4Calculated as merchandise revenue less merchandise costs.  
5Calculated as merchandise contribution divided by merchandise revenue.  
   

Merchandise contribution for the first quarter of 2026 decreased by $14.1 million, or 12.0%, compared to the first quarter of 2025, while merchandise margin increased by 70 basis points to 33.9% for the first quarter of 2025 compared to 33.2% for the prior year period. The decrease in merchandise contribution was due to a $13.7 million decrease related to retail stores that were closed or converted to dealer locations and a $0.6 million decrease in same store merchandise contribution.

Fuel contribution for the first quarter of 2026 increased by $8.0 million, or 9.4%, compared to the first quarter of 2025, primarily due to a same store fuel contribution increase of $15.3 million, partially offset by a $7.8 million decrease in retail fuel contribution related to retail stores that were closed or converted to dealer locations. Fuel margin of 47.9 cents per gallon increased 10.0 cents per gallon compared to the first quarter of 2025.

For the first quarter of 2026, site operating expenses decreased by $21.4 million, or 12.1%, compared to the first quarter of 2025 primarily due to $26.7 million of reduced expenses related to retail stores that were closed or converted to dealer locations, partially offset by an increase in same store operating expenses of $4.8 million, or 3.3%, primarily due to higher personnel costs, credit card fees and rent.


Wholesale

  For the Three Months

Ended March 31,
 
  2026     2025  
  (in thousands)  
Fuel gallons sold – fuel supply locations   198,400       191,077  
Fuel gallons sold – consignment agent locations   35,540       36,515  
Fuel contribution1– fuel supply locations $ 12,662     $ 11,453  
Fuel contribution1– consignment agent locations $ 10,229     $ 8,594  
Fuel margin, cents per gallon2– fuel supply locations   6.4       6.0  
Fuel margin, cents per gallon2– consignment agent locations   28.8       23.5  
           
1Calculated as fuel revenue less fuel costs; excludes the fixed margin or fixed fee paid to the GPMP segment for the cost of fuel.  
2Calculated as fuel contribution divided by fuel gallons sold.  
Note: Comparable wholesale sites exclude retail stores converted to dealer locations until the first quarter in which these dealer locations had a full quarter of wholesale activity in the prior year. Refer toUse of Non-GAAP Measuresbelow.  
   

For the first quarter of 2026, wholesale operating income increased by $4.4 million compared to the first quarter of 2025 as a result of additional operating income from retail stores converted to dealer locations combined with increased operating income at comparable wholesale sites.

For the first quarter of 2026, fuel contribution increased by $2.8 million compared to the first quarter of 2025. Fuel contribution for the first quarter of 2026 at fuel supply locations increased by $1.2 million due to incremental contribution from retail stores converted to dealer locations, which was partially offset by lower fuel contribution at comparable wholesale sites. Fuel contribution for the first quarter of 2026 at consignment agent locations increased $1.6 million due to incremental contribution from retail stores converted to dealer locations and higher fuel contribution at comparable wholesale site. Fuel margin per gallon increased, compared to the first quarter of 2025, 0.4 cents per gallon at fuel supply locations and 5.3 cents per gallon at consignment agent locations, primarily as a result of significant volatility in the fuel market due to the geopolitical environment and increased prompt pay discounts related to higher fuel costs.

For the first quarter of 2026, other revenues, net increased by $6.2 million, and site operating expenses increased by $5.2 million, in each case as compared to the first quarter of 2025, resulting primarily from retail stores converted to dealer locations.


Fleet Fueling

  For the Three Months
Ended March 31,
 
  2026     2025  
  (in thousands)  
Fuel gallons sold – proprietary cardlock locations   30,517       31,918  
Fuel gallons sold – third-party cardlock locations   3,446       3,175  
Fuel contribution1– proprietary cardlock locations $ 15,942     $ 14,706  
Fuel contribution1– third-party cardlock locations $ 803     $ 596  
Fuel margin, cents per gallon2– proprietary cardlock
locations
  52.2       46.1  
Fuel margin, cents per gallon2– third-party cardlock
locations
  23.4       18.7  
           
1Calculated as fuel revenue less fuel costs; excludes the fixed margin or fixed fee paid to the GPMP segment for the cost of fuel.  
2Calculated as fuel contribution divided by fuel gallons sold.  
   

Fuel contribution for the first quarter of 2026 increased by $1.4 million compared to the first quarter of 2025. At proprietary cardlocks, fuel contribution increased by $1.2 million, and fuel margin per gallon also increased for the first quarter of 2026 compared to the first quarter of 2025. At third-party cardlock locations, fuel contribution increased $0.2 million, and fuel margin per gallon also increased for the first quarter of 2026 compared to the first quarter of 2025. These increases were primarily due to favorable diesel margins as a result of significant volatility in the fuel market due to the geopolitical environment.

Liquidity and Capital Expenditures

As of March 31, 2026, the Company’s total liquidity was approximately $1.1 billion, consisting of approximately $272 million of cash and cash equivalents and approximately $794 million of availability under the Company’s lines of credit. Outstanding debt was approximately $704 million, resulting in net debt of approximately $432 million. The APC IPO in February 2026 bolstered the Company’s liquidity position, as the Company used the proceeds to repay $206.7 million of indebtedness. Capital expenditures were $30.9 million for the first quarter of 2026, including investments in NTI retail stores and fleet fueling locations, remodeling of new format stores, EV chargers, upgrades to fuel dispensers and other investments in stores.

Quarterly Dividend

The Company’s ability to return cash to its stockholders through its cash dividend program is consistent with its capital allocation framework and reflects the Company’s confidence in the strength of its cash generation ability and strong financial position.

The Board declared a quarterly dividend of $0.03 per share of common stock to be paid on May 29, 2026 to stockholders of record as of May 18, 2026.

Company-Operated Retail Store Count and Segment Update

The following tables present certain information regarding changes in the retail, wholesale and fleet fueling segments for the periods presented:

  For the Three Months

Ended March 31,
 
Retail Segment 2026     2025  
Number of sites at beginning of period   1,118       1,389  
Newly opened or reopened sites   2       2  
Company-controlled sites converted to          
consignment or fuel supply locations, net   (41 )     (59 )
Sites closed, divested or converted to rentals         (3 )
Number of sites at end of period   1,079       1,329  

  For the Three Months

Ended March 31,
 
Wholesale Segment

1
2026     2025  
Number of sites at beginning of period   2,099       1,922  
Newly opened or reopened sites2   11       6  
Consignment or fuel supply locations converted          
from Company-controlled sites, net   41       59  
Closed or divested sites   (25 )     (26 )
Number of sites at end of period   2,126       1,961  
           
1Excludes bulk and spot purchasers.  
2Includes all signed fuel supply agreements irrespective of fuel distribution commencement date.  

  For the Three Months

Ended March 31,
 
Fleet Fueling Segment 2026     2025  
Number of sites at beginning of period   295       280  
Newly opened or reopened sites   1       1  
Closed or divested sites   (4 )     (1 )
Number of sites at end of period   292       280  
               

Full Year 2026 Guidance

The Company is not updating its guidance disclosed in February 2026, which expected full year 2026 Adjusted EBITDA to range between $245 million and $265 million, with an assumed range of average retail fuel margin from 41.5 to 43.5 cents per gallon for the year.

The Company is not providing guidance on net income at this time due to the unavailability of certain required inputs that are not available without unreasonable efforts, including depreciation and amortization related to its capital allocation as part of its focus on strategic and organic growth.

Conference Call and Webcast Details

The Company will host a conference call today, May 7, 2026, to discuss these results at 9:00 a.m. Eastern Time. Investors and analysts interested in participating in the live call can dial 877-605-1792 or 201-689-8728.

A simultaneous, live webcast will also be available on the Investor Relations section of the Company’s website at https://www.arkocorp.com/news-events/ir-calendar. The webcast will be archived for 30 days.

About ARKO Corp.

ARKO Corp. (Nasdaq: ARKO) is a Fortune 500 company that is one of the largest operators of convenience stores and wholesalers of fuel in the United States. Based in Richmond, VA, our retail segment operates retail convenience stores under more than 25 regional store brands in the District of Columbia and more than 30 states across the Mid-Atlantic, Midwestern, Northeastern, Southeastern and Southwestern U.S. Our highly recognizable Family of Community Brands offers delicious, prepared foods, beer, snacks, candy, hot and cold beverages, and multiple popular quick serve restaurant brands. Our wholesale segment supplies fuel to independent dealers and consignment agents; our fleet fueling segment includes the operation of proprietary and third-party cardlock locations (unstaffed fueling locations), and commissions from the sales of fuel using proprietary fuel cards that provide customers access to a nationwide network of fueling sites; and our GPMP segment primarily engages in inter-segment transactions related to the wholesale distribution of fuel to substantially all of our sites that sell fuel in the retail, wholesale and fleet fueling segments. In February 2026, we completed the initial public offering of our subsidiary ARKO Petroleum Corp. (Nasdaq: APC), which is the primary operating entity for the wholesale, fleet fueling, and GPMP segments. To learn more about GPM stores, visit: www.gpminvestments.com. To learn more about ARKO, visit: www.arkocorp.com. To learn more about APC, visit: www.arkopetroleum.com.

Forward-Looking Statements

This document includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, the Company’s expected financial and operational results and the related assumptions underlying its expected results. These forward-looking statements are distinguished by use of words such as “accretive,” “anticipate,” “aim,” “believe,” “continue,” “could,” “estimate,” “expect,” “guidance,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and the negative of these terms, and similar references to future periods. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to, among other things, changes in economic, business and market conditions; the Company’s ability to maintain the listing of its common stock on the Nasdaq Stock Market; changes in its strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; expansion plans and opportunities; changes in the markets in which the Company competes; changes in applicable laws or regulations, including those relating to environmental matters; market conditions and global and economic factors beyond its control; the success of the Company’s transformation plan, including the dealerization of retail stores; the impact of APC operating as a public company; and the outcome of any known or unknown litigation and regulatory proceedings. Detailed information about these factors and additional important factors can be found in the documents that the Company files with the Securities and Exchange Commission, such as Form 10-K, Form 10-Q and Form 8-K. Forward-looking statements speak only as of the date the statements were made. The Company does not undertake an obligation to update forward-looking information, except to the extent required by applicable law.

Use of Non-GAAP Measures

The Company discloses certain measures on a “same store basis,” which is a non-GAAP measure. Information disclosed on a “same store basis” excludes the results of any store that is not a “same store” for the applicable period. A store is considered a same store beginning in the first quarter in which the store had a full quarter of activity in the prior year. The Company believes that this information is useful for its investors, securities analysts, and other interested parties by providing greater comparability regarding its ongoing operating performance. Neither this measure nor those described below should be considered an alternative to measurements presented in accordance with generally accepted accounting principles in the United States (“GAAP”).

The Company discloses certain measures on a “comparable wholesale sites” basis, which is a non-GAAP measure. Information disclosed on a “comparable wholesale sites” basis excludes wholesale sites added through retail stores converted to dealer locations until the first quarter in which these sites had a full quarter of wholesale activity in the prior year. The Company believes that this information is useful for its investors, securities analysts, and other interested parties by providing greater comparability regarding its ongoing operating performance.

The Company defines EBITDA as net income (loss) including net income attributable to non-controlling interests before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding the gain or loss on disposal of assets, impairment charges, acquisition and divestiture costs, share-based compensation expense, other non-cash items, certain litigation expenses, and other unusual or non-recurring charges. Both EBITDA and Adjusted EBITDA are non-GAAP financial measures.

The Company uses EBITDA and Adjusted EBITDA for operational and financial decision-making and believe these measures are useful in evaluating its performance because they eliminate certain items that it does not consider indicators of its operating performance. EBITDA and Adjusted EBITDA are also used by many of its investors, securities analysts, and other interested parties in evaluating its operational and financial performance across reporting periods. The Company believes that the presentation of EBITDA and Adjusted EBITDA provides useful information to investors by allowing an understanding of key measures that it uses internally for operational decision-making, budgeting, evaluating acquisition targets, and assessing its operating performance.

EBITDA and Adjusted EBITDA should not be considered as alternatives to any financial measure presented in accordance with GAAP, including net income (loss). These non-GAAP measures have limitations as analytical tools and should not be considered in isolation, or as substitutes for the analysis of its results as reported under GAAP. The Company strongly encourages investors to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

Because non-GAAP financial measures are not standardized, same store measures, comparable wholesale sites, EBITDA and Adjusted EBITDA, as defined by the Company, may not be comparable to similarly titled measures reported by other companies. It therefore may not be possible to compare the Company’s use of these non-GAAP financial measures with those used by other companies.

Company Contact

Jordan Mann
ARKO Corp.
[email protected]

Investor Contact

Sean Mansouri, CFA
Elevate IR
(720) 330-2829
[email protected]

  Condensed Consolidated Statements of Operations  
  (Unaudited)  
  For the Three Months

Ended March 31,
 
  2026     2025  
  (in thousands, except per share amounts)  
Revenues:          
Fuel revenue $ 1,434,658     $ 1,447,484  
Merchandise revenue   305,410       354,485  
Other revenues, net   31,798       27,504  
Total revenues   1,771,866       1,829,473  
Operating expenses:          
Fuel costs   1,300,770       1,325,624  
Merchandise costs   201,900       236,915  
Site operating expenses   182,747       199,981  
General and administrative expenses   39,998       41,613  
Depreciation and amortization   32,371       34,887  
Total operating expenses   1,757,786       1,839,020  
Other expenses, net   4,043       2,217  
Operating income (loss)   10,037       (11,764 )
Interest and other financial income   2,567       9,475  
Interest and other financial expenses   (20,712 )     (23,326 )
Loss before income taxes   (8,108 )     (25,615 )
Income tax benefit   2,496       12,922  
Income from equity investment   19       21  
Net loss   (5,593 )     (12,672 )
Less: Net income attributable to non-controlling interests   1,048        
Net loss attributable to ARKO Corp. $ (6,641 )   $ (12,672 )
Series A redeemable preferred stock dividends   (1,418 )     (1,418 )
Net loss attributable to common shareholders $ (8,059 )   $ (14,090 )
Net loss per share attributable to common
shareholders – basic and diluted
$ (0.07 )   $ (0.12 )
Weighted average shares outstanding:          
Basic and diluted   111,324       115,883  
               

  Condensed Consolidated Balance Sheets  
  (Unaudited)  
  March 31, 2026     December 31, 2025  
  (in thousands)  
Assets          
Current assets:          
Cash and cash equivalents $ 272,115     $ 305,004  
Restricted cash   17,029       18,710  
Short-term investments   7,212       6,465  
Trade receivables, net   160,336       87,331  
Inventory   206,335       190,707  
Other current assets   106,649       109,520  
Total current assets   769,676       717,737  
Non-current assets:          
Property and equipment, net   750,615       739,570  
Right-of-use assets under operating leases   1,328,394       1,340,450  
Right-of-use assets under financing leases, net   135,289       144,601  
Goodwill   299,973       299,973  
Intangible assets, net   154,596       160,136  
Equity investment   3,136       3,117  
Deferred tax asset   68,101       62,625  
Other non-current assets   68,984       66,603  
Total assets $ 3,578,764     $ 3,534,812  
Liabilities          
Current liabilities:          
Long-term debt, current portion $ 13,398     $ 36,676  
Accounts payable   202,266       156,616  
Other current liabilities   173,317       148,340  
Operating leases, current portion   79,783       78,162  
Financing leases, current portion   6,310       13,239  
Total current liabilities   475,074       433,033  
Non-current liabilities:          
Long-term debt, net   691,048       875,469  
Asset retirement obligation   89,742       89,304  
Operating leases   1,364,430       1,374,101  
Financing leases   198,099       199,691  
Other non-current liabilities   200,312       195,975  
Total liabilities   3,018,705       3,167,573  
           
Series A redeemable preferred stock   100,000       100,000  
           
Shareholders’ equity:          
Common stock   11       11  
Treasury stock   (138,584 )     (134,293 )
Additional paid-in capital   435,736       291,853  
Accumulated other comprehensive income   9,119       9,119  
Retained earnings   89,124       100,549  
Total shareholders’ equity   395,406       267,239  
Non-controlling interest   64,653        
Total equity   460,059       267,239  
Total liabilities, redeemable preferred stock and equity $ 3,578,764     $ 3,534,812  
               

  Condensed Consolidated Statements of Cash Flows  
  (Unaudited)  
  For the Three Months

Ended March 31,
 
  2026     2025  
  (in thousands)  
Cash flows from operating activities:          
Net loss $ (5,593 )   $ (12,672 )
Adjustments to reconcile net loss to net
cash provided by operating activities:
         
Depreciation and amortization   32,371       34,887  
Deferred income taxes   (5,476 )     (15,386 )
Loss on disposal of assets and impairment charges   2,073       1,528  
Foreign currency (gain) loss   (6 )     16  
Amortization of deferred financing costs and
debt discount
  909       664  
Amortization of deferred income   (5,826 )     (4,990 )
Accretion of asset retirement obligation   595       608  
Non-cash rent   2,380       3,307  
Charges to allowance for credit losses   282       217  
Income from equity investment   (19 )     (21 )
Share-based compensation   3,981       3,336  
Fair value adjustment of financial assets and
liabilities
  282       (7,059 )
Other operating activities, net         20  
Changes in assets and liabilities:          
Increase in trade receivables   (73,287 )     (14,431 )
(Increase) decrease in inventory   (15,628 )     10,575  
Decrease in other assets   2,178       5,325  
Increase in accounts payable   44,401       6,694  
Increase in other current liabilities   25,091       17,370  
Decrease in asset retirement obligation   (246 )     (317 )
Increase in non-current liabilities   10,208       13,731  
Net cash provided by operating activities   18,670       43,402  
Cash flows from investing activities:          
Purchase of property and equipment   (30,279 )     (27,392 )
Proceeds from sale of property and equipment   925       473  
Loans to equity investment, net         15  
Net cash used in investing activities   (29,354 )     (26,904 )
Cash flows from financing activities:          
Receipt of long-term debt, net   689        
Repayment of long-term debt   (214,451 )     (5,690 )
Principal payments on financing leases   (8,381 )     (1,380 )
Issuance of shares in APC IPO, net of underwriting discounts and commissions   210,426        
Payment of APC IPO costs   (3,105 )      
Common stock repurchased   (4,291 )     (7,382 )
Dividends paid on common stock   (3,366 )     (3,495 )
Dividends paid on redeemable preferred stock   (1,418 )     (1,418 )
Net cash used in financing activities   (23,897 )     (19,365 )
Net decrease in cash and cash

equivalents and restricted cash
  (34,581 )     (2,867 )
Effect of exchange rate on cash and cash
equivalents and restricted cash
  11       (4 )
Cash and cash equivalents and restricted cash,
beginning of period
  323,714       292,408  
Cash and cash equivalents and restricted cash,

end of period
$ 289,144     $ 289,537  
               

Supplemental Disclosure of Non-GAAP Financial Information

    Reconciliation of Net Loss to EBITDA and Adjusted EBITDA  
             
    For the Three Months

Ended March 31,
 
    2026     2025  
    (in thousands)  
Net loss, including net income attributable to non-controlling

interests
  $ (5,593 )   $ (12,672 )
Interest and other financing expenses, net     18,145       13,851  
Income tax benefit     (2,496 )     (12,922 )
Depreciation and amortization     32,371       34,887  
EBITDA     42,427       23,144  
Acquisition and divestiture costs (a)     1,998       1,150  
APC IPO Costs (b)     363        
Loss on disposal of assets and impairment charges (c)     2,073       1,528  
Share-based compensation expense (d)     3,981       3,336  
Income from equity investment (e)     (19 )     (21 )
Adjustment to contingent consideration (f)           (66 )
Expenses related to wage and hour claim settlement (g)           2,023  
Other (h)     104       (239 )
Adjusted EBITDA   $ 50,927     $ 30,855  
             
Additional information            
Non-cash rent expense (i)   $ 2,380     $ 3,307  
             
(a) Eliminates costs incurred that are directly attributable to business acquisitions and divestitures (including conversion of retail stores to dealer locations) and salaries of employees whose primary job function is to execute the Company’s acquisition and divestiture strategy and facilitate integration of acquired operations.  
(b) Eliminates one-time costs incurred related to the APC IPO, which closed on February 13, 2026.  
(c) Eliminates the non-cash loss from the sale or disposal of property and equipment, the loss recognized upon the sale of related leased assets, and impairment charges on property and equipment and right-of-use assets related to closed and non-performing sites.  
(d) Eliminates non-cash share-based compensation expense related to the equity incentive program in place to incentivize, retain, and motivate the Company’s employees and members of the Board.  
(e) Eliminates the Company’s share of income attributable to its unconsolidated equity investment.  
(f) Eliminates fair value adjustments primarily related to the contingent consideration owed to the seller for the 2020 Empire acquisition.  
(g) Eliminates non-recurring expenses accrued in net loss related to a wage and hour collective action settlement.  
(h) Eliminates other unusual or non-recurring items that the Company does not consider to be meaningful in assessing operating performance.  
(i) Non-cash rent expense reflects the extent to which GAAP rent expense recognized exceeded (or was less than) cash rent payments. GAAP rent expense varies depending on the terms of the Company’s lease portfolio. For newer leases, rent expense recognized typically exceeds cash rent payments, whereas, for more mature leases, rent expense recognized is typically less than cash rent payments.  
   

Supplemental Disclosures of Segment Information


Retail Segment

  For the Three Months

Ended March 31,
 
  2026     2025  
  (in thousands)  
Revenues:          
Fuel revenue $ 627,060     $ 690,686  
Merchandise revenue   305,410       354,485  
Other revenues, net   12,696       14,547  
Total revenues   945,166       1,059,718  
Operating expenses:          
Fuel costs1   533,794       605,413  
Merchandise costs   201,900       236,915  
Site operating expenses   155,873       177,239  
Total operating expenses   891,567       1,019,567  
Operating income $ 53,599     $ 40,151  
           
1Excludes the fixed margin or fixed fee paid to the GPMP segment for the cost of fuel.  


Wholesale Segment

  For the Three Months

Ended March 31,
 
  2026     2025  
  (in thousands)  
Revenues:          
Fuel revenue $ 673,855     $ 630,060  
Other revenues, net   16,530       10,352  
Other revenues, net – inter-segment   524        
Total revenues   690,909       640,412  
Operating expenses:          
Fuel costs1   650,964       610,013  
Site operating expenses   16,933       11,769  
Total operating expenses   667,897       621,782  
Operating income $ 23,012     $ 18,630  
           
1Excludes the fixed margin or fixed fee paid to the GPMP segment for the cost of fuel.  
   


Fleet Fueling Segment

  For the Three Months

Ended March 31,
 
  2026     2025  
  (in thousands)  
Revenues:          
Fuel revenue $ 127,299     $ 118,406  
Other revenues, net   2,241       2,118  
Total revenues   129,540       120,524  
Operating expenses:          
Fuel costs1   110,554       103,104  
Site operating expenses   7,031       6,428  
Total operating expenses   117,585       109,532  
Operating income $ 11,955     $ 10,992  
           
1Excludes the fixed margin or fixed fee paid to the GPMP segment for the cost of fuel.  
   


GPMP Segment

  For the Three Months

Ended March 31,
 
  2026     2025  
  (in thousands)  
Revenues:          
Fuel revenue – inter-segment1 $ 1,236,968     $ 1,166,503  
Fuel revenue – external customers         496  
Other revenues, net   171       155  
Other revenues, net – inter-segment1   1,481       2,713  
Total revenues   1,238,620       1,169,867  
Operating expenses:          
Fuel costs   1,210,682       1,145,273  
General and administrative expenses   510       828  
Depreciation and amortization   1,812       1,840  
Total operating expenses   1,213,004       1,147,941  
Operating income $ 25,616     $ 21,926  
           
1Includes the fixed margin or fixed fee paid to the GPMP segment for the cost of fuel.  



MasterCraft Boat Holdings, Inc. Reports Fiscal 2026 Third Quarter Results

VONORE, Tenn., May 07, 2026 (GLOBE NEWSWIRE) — MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2026 third quarter ended March 29, 2026.

The overview, commentary, and results provided herein relate to our continuing operations, which consists of our MasterCraft and Pontoon segments.

Overview:

  • Continued expectation to complete the combination with Marine Products Corporation (“Marine Products”) shortly after our special meeting of shareholders scheduled on May 12, 2026, subject to customary closing conditions
  • Net sales for the third quarter were $78.2 million, up $2.2 million, or 3.0%, from the comparable prior-year period
  • Dealer pipeline discipline remains strong, with stabilized dealer pipelines, supported by aligned production plans and a flexible, demand-driven wholesale approach
  • Loss from continuing operations in the third quarter was ($0.7) million, or ($0.04) per diluted share, down from prior-year income of $3.8 million, or $0.23 per diluted share, primarily due to one-time transaction costs related to the pending Marine Products combination
  • Adjusted Net Income, a non-GAAP measure, was $7.2 million, or $0.45 per diluted share, up from $5.0 million, or $0.30 per diluted share, in the prior-year period
  • Adjusted EBITDA, a non-GAAP measure, was $10.7 million, up $3.2 million from the comparable prior-year period
  • Ended the third quarter with cash and investments of $84.6 million

Brad Nelson, Chief Executive Officer, commented, “We delivered results that outperformed our expectations during the third quarter, driven by disciplined execution across our business and continued new product momentum. In a market that’s evolving week to week, we’ve remained focused on our core strengths—delivering operational efficiencies, aligning production with demand, and differentiated innovation that resonates with customers and dealers.”

Nelson continued, “Within MasterCraft, premium product momentum continues to build across the lineup. Last month, we announced the reintroduction of the X23, marking the return of a historic name in our portfolio and completing the next-generation X-series.”

Third Quarter Results

For the third quarter of fiscal 2026, MasterCraft Boat Holdings, Inc. reported consolidated net sales of $78.2 million, up $2.2 million from the third quarter of fiscal 2025. The increase in net sales was primarily due to favorable model mix and options sales, increased prices, and decreased dealer incentives, partially offset by lower unit volumes.

Gross margin percentage increased 420 basis points during the third quarter of fiscal 2026, compared to the prior-year period. Higher margins were primarily the result of increased net sales, as discussed above, combined with effective cost controls.

Operating expenses increased $9.2 million for the third quarter of fiscal 2026, compared to the prior-year period, due to business development and consulting costs related to the combination with Marine Products, increased selling and marketing costs, and consulting costs related to the implementation of our enterprise resource planning system (“ERP implementation costs”).

Loss from continuing operations was ($0.7) million for the third quarter of fiscal 2026, compared to income from continuing operations of $3.8 million in the prior-year period. Diluted loss from continuing operations per share was ($0.04), compared to diluted income from continuing operations per share of $0.23 for the third quarter of fiscal 2025.

Adjusted Net income was $7.2 million for the third quarter of fiscal 2026, or $0.45 per diluted share, compared to $5.0 million, or $0.30 per diluted share, in the prior-year period.

Adjusted EBITDA was $10.7 million for the third quarter of fiscal 2026, compared to $7.5 million in the prior-year period. Adjusted EBITDA margin was 13.7% for the third quarter, up from 9.9% for the prior-year period.

See “Non-GAAP Measures” below for a reconciliation of Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income, Adjusted Net Income per share, and Free Cash Flow, which we refer to collectively as the “Non-GAAP Measures”, to the most directly comparable financial measures presented in accordance with GAAP.

Combination with Marine Products Corporation

On February 5, 2026, we announced that we have entered into a definitive agreement under which we will merge with Marine Products, a leading manufacturer of recreation and sport fishing powerboats, in a cash and stock transaction. Our special meeting of shareholders is scheduled for May 12, 2026, and we expect to close shortly thereafter, subject to customary closing conditions.

Outlook

Concluded Nelson, “Looking ahead, we remain confident and credible in our ability to navigate the current macroeconomic environment by remaining disciplined, agile, and focusing on our strengths. With a strong balance sheet, a variable operating model, and a premium product portfolio that continues to resonate, we believe we’re well positioned as we move through the remainder of fiscal 2026 and into the next cycle.”

The Company’s outlook is as follows:

  • For full year fiscal 2026, we now expect consolidated net sales to be $312 million, with Adjusted EBITDA of $40 million, and Adjusted Earnings per share of $1.65. We now expect capital expenditures to be approximately $8 million for the year.

The outlook provided does not include the pending combination with Marine Products.

Conference Call and Webcast Information

MasterCraft Boat Holdings, Inc. will host a live conference call and webcast to discuss fiscal third quarter 2026 results today, May 7, 2026, at 8:30 a.m. ET. Participants may access the conference call live via webcast on the investor section of the Company’s website, Investors.MasterCraft.com, by clicking on the webcast icon. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company’s website.

About MasterCraft Boat Holdings, Inc.

Headquartered in Vonore, Tenn., MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) is a leading innovator, designer, manufacturer and marketer of recreational powerboats through its three brands, MasterCraft, Crest, and Balise. For more information about MasterCraft Boat Holdings, and its three brands, visit: Investors.MasterCraft.com, www.MasterCraft.com, www.CrestPontoonBoats.com, and www.BalisePontoonBoats.com.

Forward-Looking Statements

This press release includes forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Forward-looking statements can often be identified by such words and phrases as “believes,” “anticipates,” “expects,” “intends,” “estimates,” “may,” “will,” “should,” “continue” and similar expressions, comparable terminology or the negative thereof, and include statements in this press release concerning economic uncertainty, the resilience of our business model, our intention to drive value, and our financial outlook.

Forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, including, but not limited to: changes in interest rates, general economic conditions, changes in trade priorities, policies and regulations, including increases or changes in duties, current and potentially new tariffs and quotas and other similar measures, as well potential direct and indirect impact of reciprocal tariffs and other actions and uncertainty with respect to potential recovery of tariffs paid that have been determined unlawful, demand for our products, persistent inflationary pressures, changes in consumer preferences, competition within our industry, our ability to maintain a reliable network of dealers, including new dealers in international locations, our ability to cooperate with our strategic partners, elevated inventories resulting in increased costs for dealers, our ability to manage our manufacturing levels and our fixed cost base, the successful introduction of our new products, geopolitical conflicts and other political developments, financial institution disruptions, our ability to consummate the pending combination with Marine Products on the proposed terms or on the proposed timeline, or at all, including risks and uncertainties related to securing the necessary regulatory and stockholder approvals and the satisfaction of other closing conditions; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive agreement relating to the transaction with Marine Products, effects relating to the pending combination with Marine Products, including on the market price of our common stock and our relationships with customers, employees, dealers and suppliers, and the risk of potential stockholder litigation associated with the pending combination with Marine Products. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, filed with the Securities and Exchange Commission (the “SEC”) on August 27, 2025, could cause actual results to differ materially from those indicated by the forward-looking statements. The discussion of these risks is specifically incorporated by reference into this press release.

Any such forward-looking statements represent management’s estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. We undertake no obligation (and we expressly disclaim any obligation) to update or supplement any forward-looking statements that may become untrue or cause our views to change, whether because of new information, future events, changes in assumptions or otherwise. Comparison of results for current and prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

Use of Non-GAAP Financial Measures

To supplement the Company’s consolidated financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”), the Company uses certain non-GAAP financial measures in this release. Reconciliations of the Non-GAAP measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables immediately following the consolidated statements of operations. The Non-GAAP Measures have limitations as analytical tools and should not be considered in isolation or as a substitute for the Company’s financial results prepared in accordance with GAAP.

Results of Operations for the Three and Nine Months Ended March 29, 2026


MASTERCRAFT BOAT HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS


(Dollars in thousands, except per share data)

             
    Three Months Ended     Nine Months Ended  
    March 29,     March 30,     March 29,     March 30,  
    2026     2025     2026     2025  
                   
Net sales   $ 78,206     $ 75,960     $ 218,967     $ 204,687  
Cost of sales     58,664       60,195       168,502       166,232  
Gross profit     19,542       15,765       50,465       38,455  
Operating expenses:                        
Selling and marketing     3,360       2,845       9,649       8,543  
General and administrative     17,030       8,356       34,267       23,258  
Amortization of other intangible assets     450       450       1,350       1,350  
Total operating expenses     20,840       11,651       45,266       33,151  
Operating income (loss)     (1,298 )     4,114       5,199       5,304  
Other income (expense):                        
Interest expense     (58 )           (146 )     (1,169 )
Interest income     760       760       2,257       2,649  
Loss on extinguishment of debt     (71 )           (71 )      
Income (loss) before income tax expense     (667 )     4,874       7,239       6,784  
Income tax expense     49       1,053       1,811       1,521  
Income (loss) from continuing operations     (716 )     3,821       5,428       5,263  
Loss from discontinued operations, net of tax     (26 )     (78 )     (7 )     (3,917 )
Net income (loss)   $ (742 )   $ 3,743     $ 5,421     $ 1,346  
                         
Income (loss) per share                        
Basic                        
Continuing operations   $ (0.04 )   $ 0.23     $ 0.34     $ 0.32  
Discontinued operations     (0.01 )                 (0.24 )
Net income (loss)   $ (0.05 )   $ 0.23     $ 0.34     $ 0.08  
                         
Diluted                        
Continuing operations   $ (0.04 )   $ 0.23     $ 0.33     $ 0.32  
Discontinued operations     (0.01 )                 (0.24 )
Net income (loss)   $ (0.05 )   $ 0.23     $ 0.33     $ 0.08  
                         
Weighted average shares used for computation of:                        
Basic earnings per share     16,136,132       16,414,340       16,147,425       16,471,352  
Diluted earnings per share     16,136,132       16,540,345       16,263,844       16,554,235  

MASTERCRAFT BOAT HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS


(Dollars in thousands, except per share data)

             
    March 29,     June 30,  
    2026     2025  
ASSETS            
CURRENT ASSETS:            
Cash and cash equivalents   $ 75,403     $ 28,926  
Short-term investments     9,220       50,518  
Accounts receivable, net of allowances of $254 and $156, respectively     11,230       4,086  
Income tax receivable     1,740       208  
Inventories, net     34,769       30,469  
Prepaid expenses and other current assets     9,484       7,006  
Total current assets     141,846       121,213  
Property, plant and equipment, net     53,517       53,576  
Goodwill     28,493       28,493  
Other intangible assets, net     30,500       31,850  
Deferred income taxes     17,569       18,914  
Other long-term assets     5,927       5,902  
Total assets   $ 277,852     $ 259,948  
LIABILITIES AND EQUITY            
CURRENT LIABILITIES:            
Accounts payable   $ 21,895     $ 8,255  
Income tax payable     1,773       1,773  
Accrued expenses and other current liabilities     53,884       55,182  
Total current liabilities     77,552       65,210  
Unrecognized tax positions     9,346       9,067  
Other long-term liabilities     1,702       2,085  
Total liabilities     88,600       76,362  
COMMITMENTS AND CONTINGENCIES            
EQUITY:            
Common stock, $.01 par value per share — authorized, 100,000,000 shares; issued and outstanding, 16,279,890 shares at March 29, 2026 and 16,406,788 shares at June 30, 2025     163       164  
Additional paid-in capital     52,805       52,559  
Retained earnings     136,084       130,663  
MasterCraft Boat Holdings, Inc. equity     189,052       183,386  
Noncontrolling interest     200       200  
Total equity     189,252       183,586  
Total liabilities and equity   $ 277,852     $ 259,948  
                 


Supplemental Operating Data

The following table presents certain supplemental operating data for the periods indicated:

    Three Months Ended   Nine Months Ended
    March 29,     March 30,             March 29,     March 30,          
    2026     2025     Change   2026     2025     Change
    (Dollars in thousands)
Unit sales volume:                                        
MasterCraft     409       422       (3.1 ) %     1,195       1,196       (0.1 ) %
Pontoon     162       197       (17.8 ) %     524       527       (0.6 ) %
Consolidated     571       619       (7.8 ) %     1,719       1,723       (0.2 ) %
Net sales:                                        
MasterCraft   $ 66,764     $ 64,227       4.0   %   $ 186,647     $ 174,857       6.7   %
Pontoon     11,442       11,733       (2.5 ) %     32,320       29,830       8.3   %
Consolidated   $ 78,206     $ 75,960       3.0   %   $ 218,967     $ 204,687       7.0   %
Net sales per unit:                                        
MasterCraft   $ 163     $ 152       7.2   %   $ 156     $ 146       6.8   %
Pontoon     71       60       18.3   %     62       57       8.8   %
Consolidated     137       123       11.4   %     127       119       6.7   %
Gross margin     25.0 %     20.8 %   420 bps     23.0 %     18.8 %   420 bps
                                         


Non-GAAP Measures

EBITDA, Adjusted EBITDA, EBITDA margin, and Adjusted EBITDA margin

We define EBITDA as income (loss) from continuing operations, before interest, income taxes, depreciation and amortization. We define Adjusted EBITDA as EBITDA further adjusted to eliminate certain non-cash charges or other items that we do not consider to be indicative of our core and/or ongoing operations. For the periods presented herein, the adjustments include share-based compensation, senior leadership transition and organizational realignment costs, ERP implementation costs, and business development and consulting costs. We define EBITDA margin and Adjusted EBITDA margin as EBITDA and Adjusted EBITDA, respectively, each expressed as a percentage of Net sales.

Adjusted Net Income and Adjusted Net Income per share

We define Adjusted Net Income as income (loss) from continuing operations, adjusted to eliminate certain non-cash charges or other items that we do not consider to be indicative of our core and/or ongoing operations and reflecting income tax expense on adjusted net income before income taxes at our estimated annual effective tax rate. We define Adjusted Net Income per share as Adjusted Net Income divided by the weighted-average basic and diluted shares outstanding. For the periods presented herein, these adjustments include other intangible asset amortization, share-based compensation, senior leadership transition and organizational realignment costs, ERP implementation costs, and business development and consulting costs.

Free Cash Flow

We define Free Cash Flow from continuing operations as net cash flows from operating activities less purchases of property, plant, and equipment.

The Non-GAAP Measures are not measures of net income (loss), operating income (loss), or net cash flows as determined under GAAP. The Non-GAAP Measures are not measures of performance in accordance with GAAP and should not be considered as an alternative to net income (loss), net income (loss) per share, or net operating cash flows determined in accordance with GAAP. Additionally, Adjusted EBITDA is not intended to be a measure of cash flows. We believe that the inclusion of the Non-GAAP Measures is appropriate to provide additional information to investors because securities analysts and investors use the Non-GAAP Measures to assess our operating performance across periods on a consistent basis and to evaluate the relative risk of an investment in our securities. We use Adjusted Net Income and Adjusted Net Income per share to facilitate a comparison of our operating performance on a consistent basis from period to period that, when viewed in combination with our results prepared in accordance with GAAP, provides a more complete understanding of factors and trends affecting our business than does GAAP measures alone. We believe Adjusted Net Income and Adjusted Net Income per share assists our board of directors, management, investors, and other users of the financial statements in comparing our net income (loss) on a consistent basis from period to period because it removes certain non-cash items and other items that we do not consider to be indicative of our core and/or ongoing operations and reflecting income tax expense on adjusted net income before income taxes at our estimated annual effective tax rate. The Non-GAAP Measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future and the Non-GAAP Measures do not reflect any cash requirements for such replacements;
  • Certain Non-GAAP Measures do not reflect our cash expenditures, or future requirements for capital expenditures or contractual commitments;
  • Certain Non-GAAP Measures do not reflect changes in, or cash requirements for, our working capital needs;
  • Certain Non-GAAP Measures do not reflect our tax expense or any cash requirements to pay income taxes;
  • Certain Non-GAAP Measures do not reflect interest expense, or the cash requirements necessary to service interest payments on our indebtedness; and
  • Certain Non-GAAP Measures do not reflect the impact of earnings or charges resulting from matters we do not consider to be indicative of our core and/or ongoing operations, but may nonetheless have a material impact on our results of operations.

In addition, because not all companies use identical calculations, our presentation of the Non-GAAP Measures may not be comparable to similarly titled measures of other companies, including companies in our industry.

We do not provide forward-looking guidance for certain financial measures on a GAAP basis because we are unable to predict certain items contained in the GAAP measures without unreasonable efforts. These items may include acquisition-related costs, litigation charges or settlements, impairment charges, and certain other unusual adjustments.

The following table presents a reconciliation of income (loss) from continuing operations as determined in accordance with GAAP to EBITDA and Adjusted EBITDA, and income (loss) from continuing operations margin to EBITDA margin and Adjusted EBITDA margin (each expressed as a percentage of net sales) for the periods indicated:

(Dollars in thousands)   Three Months Ended   Nine Months Ended
    March 29,     % of Net   March 30,     % of Net   March 29,     % of Net   March 30,     % of Net
    2026     sales   2025     sales   2026     sales   2025     sales
Income (loss) from continuing operations   $ (716 )   -0.9 %   $ 3,821     5.0 %   $ 5,428     2.5 %   $ 5,263     2.6 %
Income tax expense     49           1,053           1,811           1,521      
Interest expense     58                     146           1,169      
Interest income     (760 )         (760 )         (2,257 )         (2,649 )    
Depreciation and amortization     2,482           2,569           6,960           7,024      
EBITDA     1,113     1.4 %     6,683     8.8 %     12,088     5.5 %     12,328     6.0 %
Share-based compensation     894           805           2,688           2,080      
Senior leadership transition and organizational realignment costs(a)                         196           448      
ERP implementation costs(b)     291                     784                
Business development and consulting costs(c)     8,425                     9,394                
Adjusted EBITDA   $ 10,723     13.7 %   $ 7,488     9.9 %   $ 25,150     11.5 %   $ 14,856     7.3 %
                                                         

The following table sets forth a reconciliation of income (loss) from continuing operations as determined in accordance with GAAP to Adjusted Net Income for the periods indicated:

(Dollars in thousands, except per share data) Three Months Ended     Nine Months Ended  
  March 29,     March 30,     March 29,     March 30,  
  2026     2025     2026     2025  
Income (loss) from continuing operations $ (716 )   $ 3,821     $ 5,428     $ 5,263  
Income tax expense   49       1,053       1,811       1,521  
Amortization of acquisition intangibles   450       450       1,350       1,350  
Share-based compensation   894       805       2,688       2,080  
Senior leadership transition and organizational realignment costs(a)               196       448  
ERP implementation costs(b)   291             784        
Business development and consulting costs(c)   8,425             9,394        
Adjusted Net Income before income taxes   9,393       6,129       21,651       10,662  
Adjusted income tax expense(d)   2,160       1,103       4,980       1,919  
Adjusted Net Income $ 7,233     $ 5,026     $ 16,671     $ 8,743  
                       
Adjusted net income per common share                      
Basic $ 0.45     $ 0.31     $ 1.03     $ 0.53  
Diluted $ 0.45     $ 0.30     $ 1.03     $ 0.53  
Weighted average shares used for the computation of(e):                      
Basic Adjusted net income per share   16,136,132       16,414,340       16,147,425       16,471,352  
Diluted Adjusted net income per share   16,136,132       16,540,345       16,263,844       16,554,235  
                               

The following table presents the reconciliation of income (loss) from continuing operations per diluted share to Adjusted Net Income per diluted share for the periods indicated:

  Three Months Ended     Nine Months Ended  
  March 29,     March 30,     March 29,     March 30,  
  2026     2025     2026     2025  
Income (loss) from continuing operations per diluted share $ (0.04 )   $ 0.23     $ 0.33     $ 0.32  
Impact of adjustments:                      
Income tax expense         0.06       0.11       0.09  
Amortization of acquisition intangibles   0.03       0.03       0.08       0.08  
Share-based compensation   0.06       0.05       0.17       0.13  
Senior leadership transition and organizational realignment costs(a)               0.01       0.03  
ERP implementation costs(b)   0.02             0.05        
Business development and consulting costs(c)   0.52             0.58        
Adjusted Net Income per diluted share before income taxes   0.59       0.37       1.33       0.65  
Impact of adjusted income tax expense on net income per diluted share before income taxes(d)   (0.14 )     (0.07 )     (0.30 )     (0.12 )
Adjusted Net Income per diluted share $ 0.45     $ 0.30     $ 1.03     $ 0.53  
                               

The following table presents the reconciliation of net cash flow by operating activities of continuing operations to Free Cash Flow for the periods presented:

    Nine Months Ended  
    March 29,     March 30,  
    2026     2025  
Net cash used in operating activities of continuing operations   $ 13,387     $ 18,457  
Less:            
Purchases of property, plant and equipment     (5,746 )     (6,606 )
Free cash flow   $ 7,641     $ 11,851  

(a) Represents amounts paid for legal fees and recruiting costs associated with the CEO and CFO transitions, as well as non-recurring severance costs incurred as part of the Company’s strategic organizational realignment undertaken in connection with the transitions.
(b) Represents consulting costs incurred in connection with the ERP system implementation.
(c) Represents non-recurring third-party business development and consulting costs and debt extinguishment costs related to the Marine Products transaction.
(d) For fiscal 2026 and 2025, income tax expense reflects an income tax rate of 23.0% and 20.0%, respectively.
(e) Represents the Weighted Average Shares used for the computation of Basic and Diluted earnings (loss) per share as presented on the Consolidated Statements of Operations to calculate Adjusted Net Income per basic and diluted share for all periods presented herein.
   

Investor Contact:

MasterCraft Boat Holdings, Inc.
Alec Harmon
Senior Director of Strategy and Investor Relations
Email: [email protected]



Annovis CEO to Present on Multi-Protein Model of Alzheimer’s Disease at Fierce Biotech Week 2026

MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, Ph.D., President and CEO, will present at Fierce Biotech Week 2026 taking place in Boston, May 12-14, 2026.

Presentation Details:

  • Title: “The Multi-Protein Reality of Alzheimer’s Disease: What the Science Has Known for Decades and What the Field Has Yet to Accept”
  • Presenter: Maria Maccecchini, Ph.D., President and CEO
  • Date: Wednesday, May 13, 2026
  • Time: 1:40 PM – 2:05 PM
  • Location: Picasso 4&5

The presentation will trace the scientific foundation for understanding AD as a disease driven by multiple neurotoxic aggregating proteins and examine the historical gap between that evidence and the field’s reliance on a single-protein approach. Dr. Maccecchini will make the case supporting the importance of the full spectrum of neurotoxic proteins – including amyloid, tau, alpha-synuclein, TDP-43, and more – in disease progression, which are not only backed by decades of scientific data but also represent a promising path forward for the AD drug development.

“Alzheimer’s disease has never been a one-protein problem, and overreliance on amyloid as the sole driver of the disease has come at a cost, hindering progress for alternative therapeutic candidates,” said Maria Maccecchini, Ph.D., President and CEO. “Annovis’ program is built exactly on the premise that simultaneous reduction of the overexpression of several aggregating proteins interrupts the toxic cascade and improves the health of nerve cells. Our lead drug buntanetap, a translational inhibitor of these proteins, has already shown meaningful clinical benefits supported by encouraging biomarker data, and is now in a pivotal Phase 3 clinical trial.”

The presentation will be followed by a Q&A discussion and is open to all participants.

Fierce Biotech Week 2026 brings together leaders across R&D, clinical development, business development, and communications to confront the industry’s most pressing challenges, from capital strategy and pipeline advancement to partnership formation and commercialization. With more than 100 biotech CEOs and founders, over 500 companies, and 15 top global pharmaceutical organizations represented, the event is built for the leaders driving consequential decisions.

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedInYouTube, and X.

Investor Alerts

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:

Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:

Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
[email protected]



urban-gro, Inc. (Nasdaq: UGRO) — Sri Lanka Cricket Confirms Lanka Premier League Season 6 Foreign Player Registration to Open 8 May 2026; Tournament to Be Played Across Four Venues in July–August 2026

Foreign player registration portal to open on 8 May 2026 and remain open until 18 May 2026; matches to be played across SSC (Colombo), RPICS (Colombo), PICS (Pallekele), and RDICS (Dambulla); tournament conducted by SLC in partnership with UGRO subsidiary The IPG Group

LAFAYETTE, Colo., May 07, 2026 (GLOBE NEWSWIRE) — urban-gro, Inc. (Nasdaq: UGRO) (“urban-gro” or the “Company”), operating through Flash Sports & Media, Inc., today noted the official media release issued by Sri Lanka Cricket (“SLC”) on 5 May 2026 confirming the foreign player registration timeline, venues, and overall schedule for Lanka Premier League (“LPL”) Season 6, as also reported by Sri Lankan sports media outlet ThePapare (Foreign player registration for LPL 2026 to begin on May 8,” ThePapare, 5 May 2026). The sixth edition of the tournament is scheduled to take place during July and August 2026, and is owned by SLC and conducted in partnership with Innovative Production Group FZ, LLC (“IPG”), the event rights holder. The Company participates in the tournament through its subsidiary IPG under existing commercial arrangements.

Season 6 — By the Numbers

Tournament window July and August 2026 (per SLC media release dated 5 May 2026)
Edition Sixth edition of the Lanka Premier League
Foreign player registration portal opens 8 May 2026
Foreign player registration portal closes 18 May 2026
Registration portal www.srilankacricket.lk
Venues SSC, Colombo; RPICS, Colombo; PICS, Pallekele; RDICS, Dambulla
League ownership Owned by Sri Lanka Cricket; conducted in partnership with The IPG Group (event rights holder)
UGRO involvement Through subsidiary Innovative Production Group FZ, LLC (IPG) under existing commercial arrangements



Confirmed Venues

Per the SLC media release, Season 6 matches will be played across four Sri Lankan international cricket venues:

  • Singhalese Sports Club (SSC) Grounds, Colombo
  • R. Premadasa International Cricket Stadium (RPICS), Colombo
  • Pallekele International Cricket Stadium (PICS), Pallekele
  • Rangiri Dambulla International Cricket Stadium (RDICS), Dambulla

Foreign Player Registration

As confirmed by SLC, the online portal for foreign player registration for LPL Season 6 will open on 8 May 2026. Once launched, the portal can be accessed at www.srilankacricket.lk and will remain open until 18 May 2026.

Strategic Context for UGRO

Following its combination with Flash Sports & Media, Inc. and the integration of IPG, the Company participates in the LPL as a sports, media, and experiential platform, with commercial exposure to the tournament’s media, sponsorship, and on-ground activations through its contractual arrangements with the league. LPL Season 6 represents the first full season in the Company’s current operating structure following the IPG integration. Actual revenues from the Company’s participation will depend on the specific terms of its contractual arrangements and on overall tournament outcomes, and may differ materially from any industry-level references included in this release.

Industry Context (Third-Party Data)

For general reference only, publicly available third-party reports describe T20 cricket as a high-engagement global format with an estimated fan base of approximately 2.5 billion across South Asia, Southeast Asia, the Caribbean, the United Kingdom, and other markets. IPL media rights, for a mature comparable league, have been publicly reported at over USD 6 billion for a five-year cycle. Third-party industry estimates have referenced local economic impact for prior LPL seasons in the USD 25–30 million range. These figures relate to the broader industry or to other leagues and are not a projection of the Company’s financial results, revenues, or economic impact from LPL Season 6, and should not be relied on as such.

Independent Media Coverage

The SLC announcement has been independently reported by Sri Lankan sports media. ThePapare, a leading Sri Lankan sports news outlet, confirmed that “Sri Lanka Cricket (SLC) announced today that the online portal for the ‘Foreign Player Registration’ for the 6th edition of the Lanka Premier League will be opened on the 8th May, 2026,” and further reported the same venue list (SSC, Colombo; RPICS, Colombo; PICS, Pallekele; and RDICS, Dambulla) and July–August 2026 tournament window referenced in this release. The full ThePapare article is available at https://www.thepapare.com/foreign-player-registration-for-lpl-2026-to-begin-on-may-8/. This independent reporting reinforces the timeline and operating framework within which the Company’s subsidiary, IPG, will participate in Season 6.

Disclaimer

The Company does not own, operate, or control the Lanka Premier League, its franchises, or any governing body. The Company’s involvement is limited to its contractual rights and services through Innovative Production Group FZ, LLC and related commercial arrangements. References to league operations, player participation, market size, or economic impact are based on third-party information or industry estimates and are provided solely for general context. The Company’s actual revenues, if any, will depend on its specific contractual arrangements and may differ materially from broader industry metrics referenced herein.

About urban-gro, Inc.

Following its recent combination with Flash Sports & Media, Inc. (“Flash”) and the integration of Innovative Production Group FZ, LLC, urban-gro, Inc. is a diversified sports, media, and experiential marketing platform focused on the creation, production, and monetization of live events, original content, and branded fan experiences. The Company operates across multiple sports and entertainment verticals, leveraging proprietary intellectual property, strategic partnerships, and experiential activations to engage audiences and deliver value for brands, sponsors, and media partners.

About Lanka Premier League

The Lanka Premier League is a professional T20 cricket tournament bringing together Sri Lankan and international players. The league is owned by Sri Lanka Cricket and operated in partnership with The IPG Group, its official event rights holder. Season 6 is scheduled to take place during July and August 2026. For additional information, visit: https://srilankacricket.lk

About Twenty20 Cricket

Twenty20 (T20) is a format of cricket in which each team plays a maximum of 20 overs. Introduced by the England and Wales Cricket Board in 2003, T20 matches are typically completed in approximately three and a half hours. For more information, visit: http://www.t20worldcup.com

Investor Relations Contact


[email protected]

Company Websites


https://flashsportsandmedia.com


https://www.theipggroup.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s expectations, beliefs, or intentions relating to its participation in connection with the Lanka Premier League, the anticipated benefits of its business combination with Flash Sports & Media, Inc., the development and commercialization of sports and media platforms, potential sponsorship, media rights and commercial opportunities, anticipated market size and growth, projected economic impact of the Lanka Premier League, and the Company’s ability to generate revenues from its activities. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “may,” “will,” “could,” “seek,” “estimate,” “potential,” or similar expressions.

These forward-looking statements are based on current expectations, estimates, and assumptions and involve known and unknown risks and uncertainties that could cause actual results and outcomes to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation: the Company’s limited role and lack of control over the operations, scheduling, governance, and commercial activities of the Lanka Premier League and its franchises; the Company’s reliance on third-party partners, including Innovative Production Group FZ LLC and other counterparties, to perform under contractual arrangements; uncertainties regarding the participation, availability, or continued involvement of players, ambassadors, or other talent referenced in this press release; the possibility that anticipated sponsorships, media rights arrangements, or other commercial opportunities may not materialize or may be delayed; the extent to which the Company is able to generate revenues, if any, from its involvement in the Lanka Premier League; risks relating to the integration of Flash Sports & Media, Inc. and the Company’s ability to realize anticipated synergies; the Company’s ability to develop, monetize, and scale its sports, media, and experiential business lines; the timing and success of expansion into new markets; the Company’s ability to establish or maintain strategic relationships and commercial arrangements; the extent to which industry developments referenced in this press release translate into opportunities for the Company; general economic, market, and industry conditions; competitive dynamics within the sports and media sectors; international, geopolitical, and regulatory risks associated with global sporting events; and the Company’s ability to maintain compliance with applicable listing standards of The Nasdaq Stock Market LLC.

In addition, certain market, industry, and economic data referenced in this press release are based on third-party sources and estimates that the Company believes to be reliable, but the Company has not independently verified such information and makes no representation as to its accuracy or completeness.

Additional factors that could cause actual results to differ materially from those described in forward-looking statements can be found in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as other filings made with the Securities and Exchange Commission, which are available at www.sec.gov.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Source: urban-gro, Inc. (Nasdaq: UGRO)



Ascendis Pharma Reports First Quarter 2026 Financial Results

– Q1 2026 revenue of €197 million for YORVIPATH
® and €44 million for SKYTROFA®

– More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1

– As of May 1, more than 60 YUVIWEL
®
enrollments since early April U.S. commercial launch

– Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million

– Conference call today at 8:00 am ET

COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update.

“The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH are cementing our position as a leading global biopharma,” said Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma. “Our strong focus on science and making a meaningful difference for patients will continue to be the fundamental driver for our success.”

Select Highlights & Anticipated 2026 Milestones

  • YORVIPATH
    (palopegteriparatide, developed as TransCon PTH)
    • YORVIPATH revenue for the first quarter of 2026 totaled €197 million, which for the U.S. includes normal seasonality and the temporary impact of additional patients supported by free drug, as well as a one-time impact in Europe Direct related to expanded market access.
    • In the U.S., more than 1,000 new patient enrollments in the first quarter of 2026.
    • As of March 31, 2026, more than 6,300 unique patient enrollments by more than 2,700 prescribing healthcare providers since launch in the U.S.
    • Outside the U.S., continued expansion of commercial launches with full reimbursement. Now available commercially or through named patient programs in 35 countries.
    • Ongoing label expansion trials through PaTHway60 (adults) and PaTHway Adolescent.
  • YUVIWEL
    (navepegritide, developed as TransCon CNP)
    • Received U.S. Food & Drug Administration (FDA) accelerated approval, indicated to increase linear growth in children 2 years of age and older with achondroplasia with open epiphyses.
    • The FDA granted orphan drug exclusivity for YUVIWEL, which will run through February 27, 2033.
    • As of May 1, 2026, more than 60 unique patient enrollments by more than 35 prescribing healthcare providers since U.S. commercial availability in April 2026.
    • Marketing Authorisation Application remains under review by the European Medicines Agency, with a decision anticipated in the fourth quarter of 2026.
    • Label expansion trial in infants with achondroplasia, reACHin, is ongoing with enrollment completion anticipated in the third quarter of 2026.
    • Phase 3 trial planned to investigate TransCon CNP monotherapy for the treatment of hypochondroplasia in the second half of the year.
  • SKYTROFA
    (lonapegsomatropin, developed as TransCon hGH)
    • SKYTROFA revenue for the first quarter of 2026 totaled €44 million.
    • Announced Week 52 data from the Phase 2 New InsiGHTS Trial in Turner syndrome that demonstrated comparable efficacy and safety to daily somatropin.
    • Ongoing Phase 3 HighLiGHts basket trial across a range of established growth disorders including idiopathic short stature (ISS), SHOX deficiency, Turner syndrome, and small for gestational age (SGA).

  • TransCon CNP + TransCon hGH Combination Therapy
    (navepegritide plus lonapegsomatropin)
    • Announced Phase 2 COACH Trial Week 52 topline results demonstrating mean annualized growth velocity that exceeded the 97th percentile of average stature children, improvements in body proportionality, and a safety profile consistent with TransCon CNP and TransCon hGH monotherapies.
    • Announced additional Week 52 results from COACH demonstrating meaningful benefits beyond linear growth, including improvements in spinal canal dimensions and lower limb alignment, along with unprecedented improvements in arm span compared to monotherapy.
    • Interim Week 78 data from COACH expected in the second quarter of 2026 with Week 104 data expected around year end.

  • Oncology Program
    (onvapegleukin alfa)
    • In the ongoing Phase 1/2 IL-BELIEVE Trial, TransCon IL-2 β/γ in combination with paclitaxel demonstrated improved median overall survival (OS) up to 10 months from 6-7 months for historical controls, with a generally well-tolerated safety profile in patients with late-stage platinum-resistant ovarian cancer, validating the science behind TransCon IL-2 β/γ.
    • As further internal oncology development does not align with our strategic focus, we have decided to discontinue internal development of TransCon IL-2 β/γ in Oncology and will explore other ways to maximize the value of this asset.

Key Financial Highlights

  • Total revenue for the first quarter of 2026 was €247 million, compared to €101 million during the same period in 2025. The year-over-year increase in revenue was primarily attributable to an increase in product revenue from YORVIPATH.
  • Operating profit for the first quarter of 2026 totaled €25 million, reflecting a margin of 10.1%. On a non-IFRS basis, operating profit was €55 million*, reflecting a margin of 22.4%*.
  • Net profit for the first quarter of 2026 totaled €629 million, or €9.75 per diluted share, including the recognition of previously unrecognized deferred tax assets of €679 million. On a non-IFRS basis, net profit was €18 million*, or €0.27 per diluted share*.
  • As of March 31, 2026, Ascendis Pharma had cash and cash equivalents totaling €573 million, which includes the impact of repurchases under the previously announced share repurchase program of €52 million and the net settlement of certain Restricted Stock Units for €8 million, compared to cash and cash equivalents totaling €616 million as of December 31, 2025.
  • Subsequent to March 31, 2026:
    • On April 20, 2026, the Company’s ordinary shares commenced trading on The Nasdaq Global Select Market, replacing the prior listing of American Depositary Shares (ADSs).
    • On May 6, 2026, Ascendis redeemed all $575 million aggregate principal amount of its outstanding 2.25% convertible notes due 2028. Within the redemption period, all holders of the convertible notes surrendered their notes for conversion, whereupon the Company delivered 3,635,813 ordinary shares, together with cash in lieu of any fractional shares. The conversion resulted in the settlement of the current liabilities of convertible notes, comprising borrowings and derivative liabilities totaling €733 million as of March 31, 2026. The carrying amount as of the settlement date will be reclassified to equity in the second quarter of 2026.
    • Entered into agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $187.5 million in cash, before transaction-related expenses. The PRV was awarded by the FDA upon approval of YUVIWEL in February 2026. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2026.

* See “Non-IFRS Financial Measures” below for definitions of these non-IFRS measures and a reconciliation to the most directly comparable IFRS measures.

First Quarter 2026 Financial Results

Total revenue for the first quarter of 2026 was €247 million, compared to €101 million during the same period in 2025. The year-over-year increase in revenue was primarily attributable to an increase in product revenue from YORVIPATH.

     
Total Revenue
(In EUR’000s)
  Three Months Ended
March 31,
    2026   2025
Revenue        
Commercial products   240,853   96,028
Services and clinical supply   5,110   3,524
Licenses   638   1,402
Total revenue   246,601   100,954
         

Revenue from Commercial Products
(In EUR’000s)
  Three Months Ended
March 31,
    2026   2025
         
         
         
         
         
Revenue from commercial products        
         
         
         
         
         
YORVIPATH®   196,896   44,688
         
         
         
         
         
SKYTROFA®   43,957   51,340
         
         
         
         
         
Total revenue from commercial products   240,853   96,028
         
         
         
         
         
         

Research and development expenses for the first quarter of 2026 were €59 million, compared to €87 million during the same period in 2025. The decrease was driven primarily by the completion of certain clinical trials and development activities within our Endocrinology Rare Disease and Oncology pipeline and the first quarter of 2026 being positively impacted by a reversal of prior period write-downs of pre-launch inventories related to YUVIWEL.

Selling, general, and administrative expenses for the first quarter of 2026 were €145 million, compared to €101 million during the same period in 2025. The increase was primarily due to the impact from commercial expansion, including global launch activities.

Total operating expenses for the first quarter of 2026 were €204 million compared to €188 million during the same period in 2025.

Operating profit for the first quarter of 2026 was €25 million, compared to an operating loss of €104 million during the same period in 2025. The increase was primarily driven by the increase in product revenue.

Net finance expenses for the first quarter of 2026 were €63 million, compared to €16 million during the same period in 2025. The increase was primarily driven by non-cash fair-value remeasurement of derivative liabilities associated with our convertible notes.

Income taxes for the first quarter of 2026 included the recognition of previously unrecognized deferred tax assets of €679 million.

For the first quarter of 2026, Ascendis Pharma reported net profit of €629 million, or €10.20 per share basic and €9.75 per share (diluted), compared to a net loss of €95 million, or €1.58 per share (basic and diluted), for the same period in 2025. Net profit for the first quarter of 2026 included the recognition of previously unrecognized deferred tax assets of €679 million.

Cash flows used in operating activities for the first quarter of 2026 were €8 million compared to €14 million used during the same period in 2025. The change primarily reflects the prior-year period benefiting from the $100 million upfront payment received under our exclusive license agreement with Novo Nordisk, which did not recur in the current period, while the current period reflects improved operating performance offset by working capital build.

As of March 31, 2026, Ascendis Pharma had cash and cash equivalents totaling €573 million, compared to €616 million as of December 31, 2025. As of March 31, 2026, Ascendis Pharma had 62,376,846 ordinary shares outstanding, including 265,251 held by the Company.

Beginning with the first quarter of 2026, Ascendis Pharma is introducing supplemental non-IFRS financial measures that management believes will help investors evaluate the Company’s underlying operating performance from period to period and enhance comparability against peer companies. The non-IFRS measures presented are not a substitute for, and should be considered together with, the comparable IFRS measures. See the table below on page 14 for specific reconciling items.

For the first quarter of 2026, non-IFRS operating profit was €55 million, compared to a non-IFRS operating loss of €79 million for the same period in 2025.

For the first quarter of 2026, non-IFRS net profit was €18 million, or €0.27 earnings per diluted share, compared to a non-IFRS net loss of €73 million, or €1.22 loss per diluted share, for the same period in 2025.

Conference Call and Webcast Information

Ascendis Pharma will host a conference call and webcast today at 8:00 am Eastern Time (ET) to discuss its first quarter 2026 financial results.

Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available in this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days.

About Ascendis Pharma A/S

Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ evolution into a leading global biopharma, (ii) Ascendis’ strong focus on science and making a meaningful difference for patients as the fundamental driver for success, (iii) anticipated timing of a regulatory decision from the European Medicines Agency, (iv) anticipated timing and plans of clinical trials and development activities, (v) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (vi) Ascendis’ use of TransCon to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA

®

, YORVIPATH

®

, and YUVIWEL

®

are trademarks owned by the Ascendis Pharma group. © May 2026 Ascendis Pharma A/S. 


Investor Contacts:

Media Contact:
Chad Fugere Melinda Baker
Ascendis Pharma Ascendis Pharma
+1 (650) 519-7494    +1 (650) 709-8875
   

FINANCIAL TABLES FOLLOW

     
Ascendis Pharma
A/S Unaudited Condensed Consolidated Statements of Profit or
(Loss) and Comprehensive Income / (Loss)
(In EUR’000s, except per share data)
  Three Months Ended
March 31,
    2026
  2025
Consolidated Statement of Profit or (Loss)        
Revenue   246,601     100,954  
Cost of sales   (17,515 )   (17,517 )
Gross profit   229,086     83,437  
Research and development expenses   (59,044 )   (86,603 )
Selling, general, and administrative expenses   (145,230 )   (101,046 )
Operating profit/(loss)   24,812     (104,212 )
Share of profit/(loss) of associates   (10,251 )   26,579  
Finance income   4,517     28,854  
Finance expenses   (67,255 )   (44,786 )
Profit/(loss) before tax   (48,177 )   (93,565 )
Income taxes (expenses)   677,516     (1,061 )
Net profit/(loss) for the period   629,339     (94,626 )
Attributable to owners of the Company   629,339     (94,626 )
Basic earnings/(loss) per share   10.20     (1.58 )
Diluted earnings/(loss) per share   9.75     (1.58 )
         
     
Consolidated Statement of Comprehensive Income or (Loss)        
Net profit/(loss) for the period   629,339     (94,626 )
Other comprehensive income/(loss)        

Items that may be reclassified subsequently to profit or (loss):
       
Exchange differences on translating foreign operations   3,058     (75 )
Other comprehensive income/(loss) for the period, net of tax   3,058     (75 )
Total comprehensive income/(loss) for the period, net of tax   632,397     (94,701 )
Attributable to owners of the Company   632,397     (94,701 )

           
Ascendis Pharma A/S
Unaudited Condensed Consolidated Statements of Financial Position
(In EUR’000s)
    March 31,
 2026



  December 31,
2025
             
Assets            
Non-current assets            
Intangible assets     3,689     3,710  
Property, plant and equipment     135,918     146,479  
Investments in associates     23,560     32,526  
Other receivables     27,367     10,870  
Deferred tax assets     690,405      
      880,939     193,585  
Current assets            
Inventories     314,342     301,533  
Trade receivables     178,676     141,333  
Income tax receivables     1,258     1,781  
Other receivables     16,673     14,582  
Prepayments     38,571     33,715  
Cash and cash equivalents     572,820     616,041  
      1,122,340     1,108,985  
Total assets     2,003,279     1,302,570  
             
Equity and liabilities            
Equity            
Share capital     8,380     8,322  
Distributable equity     479,593     (171,143 )
Total equity     487,973     (162,821 )
             
Non-current liabilities            
Borrowings     386,106     385,254  
Contract liabilities     2,437     1,123  
Deferred tax liabilities         9,623  
      388,543     396,000  
Current liabilities            

Convertible notes, due April 2028
           
Borrowings     448,176     429,391  
Derivative liabilities     290,482     256,231  
      738,658     685,622  
Other current liabilities            
Borrowings     62,382     57,141  
Contract liabilities     5,364     4,944  
Trade payables and accrued expenses     78,588     90,657  
Other liabilities     57,316     58,204  
Income tax payables     7,805     6,427  
Provisions     176,650     166,396  
      388,105     383,769  
      1,126,763     1,069,391  
Total liabilities     1,515,306     1,465,391  
Total equity and liabilities     2,003,279     1,302,570  
             

Ascendis Pharma A/S
Unaudited Condensed Consolidated Statements of Cash Flow
(In EUR’000s)
  Three Months Ended
March 31,
    2026   2025
Operating activities        
Net profit/(loss) for the period   629,339     (94,626 )
Reversal of finance income   (4,517 )   (28,854 )
Reversal of finance expenses   67,255     44,786  
Reversal of income taxes   (677,516 )   1,061  
Adjustments for non-cash items:        
Non-cash consideration relating to revenue   (638 )   (1,402 )
Share of (profit)/loss of associates   10,251     (26,579 )
Share-based payment   30,356     25,558  
Depreciation and amortization   4,220     4,545  
Impairment of property, plant and equipment       7,508  
Changes in working capital:        
Inventories   (12,813 )   2,538  
Receivables   (36,377 )   98,032  
Prepayments   (4,852 )   (5,521 )
Contract liabilities   1,735     (4,054 )
Trade payables, accrued expenses and other liabilities   (21,051 )   (40,767 )
Provisions   6,534     260  
Cash flows generated from/(used in) operations   (8,074 )   (17,515 )
Finance income received   4,518     4,208  
Finance expenses paid   (5,328 )   (954 )
Income taxes received/(paid)   1,163     (52 )
Cash flows from/(used in) operating activities   (7,721 )   (14,313 )
Investing activities        
Payments received under finance leases   959      
Acquisition of intangible assets and property, plant and equipment   (7,712 )   (703 )
Cash flows from/(used in) investing activities   (6,753 )   (703 )
Financing activities        
Repayment of borrowings   (8,580 )   (3,066 )
Proceeds from exercise of warrants   31,625     13,834  
Acquisition of treasury shares   (51,857 )   (17,396 )
Payment of withholding taxes under stock incentive programs   (8,021 )   (11,396 )
Cash flows from/(used in) financing activities   (36,833 )   (18,024 )
         
Increase/(decrease) in cash and cash equivalents   (51,307 )   (33,040 )
Cash and cash equivalents at January 1   616,041     559,543  
Effect of exchange rate changes on balances held in foreign currencies   8,086     (8,580 )
Cash and cash equivalents at March 31   572,820     517,923  
         


Non-IFRS Financial Measures

In addition to the financial information prepared in accordance with IFRS Accounting Standards (“IFRS”) as issued by the International Accounting Standards Board and as adopted by the European Union, this press release contains certain non-IFRS financial measures, including Non-IFRS Operating Profit/(Loss), Non-IFRS Net Profit/(Loss), Non-IFRS operating profit/(loss) margin, and Non-IFRS diluted earnings per share (“Non-IFRS Diluted EPS”). These non-IFRS measures are provided as supplemental information and should be considered in addition to, and not as a substitute for or superior to, the comparable measures prepared in accordance with IFRS. Management believes these non-IFRS measures support management’s, analysts’ and investors’ overall understanding of the Company’s underlying financial performance and trends and facilitate comparisons among current and past periods.

Since non-IFRS measures do not have standardized definitions and meanings, they may differ from the non-IFRS measures used by other companies, which reduces their usefulness as comparative financial measures. Because of these limitations, you should consider these adjusted financial measures alongside other IFRS financial measures. Because these non-IFRS measures are not prepared in accordance with IFRS, they should not be viewed as superior to IFRS reported measures, nor should they be used on their own or as replacements for the IFRS financial information included in this press release. Additionally, our non-IFRS measures may differ from similarly labeled measures used by other companies due to variations in calculation methods or the size and nature of adjusted items. Investors should note that several of the items excluded from these non-IFRS measures have been recognized in prior periods and may continue to be recognized in future periods.

The Company reports Non-IFRS Operating Profit/(Loss), Non-IFRS Net Profit /(Loss), Non-IFRS operating profit/(loss) margin and Non-IFRS Diluted EPS as non-IFRS measures, which exclude the following specified items:

(i) Share-based compensation expense. Although share-based compensation is a recurring expense, the Company excludes it from non-IFRS measures because the amount and timing of recognition depend on the value of the underlying equity instruments, which can fluctuate based on factors unrelated to the Company’s operating performance during the period.

(ii) Share of profit/(loss) of associates. The Company excludes its share of the profit or loss of equity-method investees because these amounts are not within the control of the Company and do not reflect the Company’s core operating performance.

(iii) Fair-value remeasurement of derivative liabilities related to the Company’s convertible notes. The Company excludes the fair-value remeasurement of derivative liabilities associated with its convertible notes because these amounts depend on movements in the Company’s share price and other market inputs and are not indicative of the Company’s underlying operating performance.

(iv) Recognition of previously unrecognized deferred tax assets. The Company excludes the one-time recognition of previously unrecognized deferred tax assets because this item reflects a reassessment of the recoverability of historical tax attributes rather than the Company’s current period operating performance.

Income taxes related to the foregoing items are adjusted accordingly, considering the individual impact of each item, the relevant tax jurisdiction, applicable tax rates, and the deductibility of the item.

For further details regarding valuation of derivative liabilities, and the recognition of previously unrecognized deferred tax assets, please refer to “Note 3 – Significant Accounting Judgements and Estimates,” contained in our Interim Report on Form 6-K, for the period ended March 31, 2026 and “Note 3 – Significant Accounting Judgements and Estimates,” contained in our Annual Report on Form 20-F, for the year ended December 31, 2025.

The following table provides a reconciliation of the most directly comparable IFRS measures to Non-IFRS Operating Profit/(Loss), Non-IFRS Net Profit/(Loss) and Non-IFRS Diluted EPS.

           
Ascendis Pharma A/S
Reconciliation of IFRS to Non-IFRS Financial Information
(unaudited, in EUR’000s, except shares and per share data)
           
    Three Months Ended
    March 31,
           
    2026
    2025
           
IFRS operating profit/(loss)   24,812       (104,212 )
Share-based compensation costs   30,356       25,558  
Total non-IFRS adjustments to operating profit/(loss)   30,356       25,558  
Non-IFRS operating profit/(loss)   55,168       (78,654 )
           
IFRS operating profit/(loss) margin (%)1   10.1 %     (103.2 %)
Non-IFRS operating profit/(loss) margin (%)1   22.4 %     (77.9 %)
           
           
IFRS Net profit/(loss)   629,339       (94,626 )
Share-based compensation costs   30,356       25,558  
Share of profit/(loss) of associates   10,251       (26,579 )
Remeasurement gain/(loss) of derivative liabilities   34,251       23,911  
Recognition of previously unrecognized deferred tax assets   (679,024 )      
Tax effects of adjustments   (7,623 )     (1,640 )
Total non-IFRS adjustments to net profit/(loss)   (611,789 )     21,250  
Non-IFRS net profit/(loss)   17,550       (73,376 )
           
Net profit/(loss) per diluted share:          
  IFRS   9.75       (1.58 )
  Diluted per share impact of total non-IFRS adjustments   (9.48 )     0.35  
  Non-IFRS   0.27       (1.22 )
           
Shares used in diluted per share calculation:          
  IFRS   64,521,948       60,018,550  
  Non-IFRS   64,521,948       60,018,550  
           
1 Defined as either IFRS or non-IFRS operating profit/(loss) divided by total revenue          



Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Enables billing under traditional Medicare and creates a pathway to ~35 million Medicare Advantage beneficiaries through future payer coverage decisions

HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that its wholly owned subsidiary, CNSide Diagnostics, LLC (“CNSide Diagnostics”), has successfully enrolled in the Medicare program and received a Provider Transaction Access Number (PTAN) from the Centers for Medicare & Medicaid Services (CMS).

This key milestone establishes CNSide Diagnostics as a Medicare-enrolled clinical laboratory, enabling the submission of claims for its CNSide® Cerebrospinal Fluid (CSF) Assay Platform, including the tumor cell enumeration (TCE) test. Claims will be reimbursed when determined to be reasonable and necessary by the Medicare Administrative Contractor (MAC) with jurisdiction over the laboratory.

“Medicare enrollment represents a critical step in our commercialization strategy,” said Russ Havranek, EVP Corporate and Commercial Strategy. “It enables access to approximately half of the U.S. Medicare population through Traditional Medicare, subject to coverage determinations, while establishing a clear pathway to expand into Medicare Advantage populations over time. Combined with our existing ~81 million commercial covered lives, this milestone strengthens our pathway to broader patient access, adoption, and revenue growth.”

Strategic and Commercial Impact

  • Expanded Billing of Traditional Medicare: Enables billing for testing furnished to Medicare Fee-For-Service beneficiaries, subject to coverage determination by our local Medicare Administrative Contractor (MAC)
  • Pathway to Medicare Advantage: Positions CNSide Diagnostics to pursue coverage with Medicare Advantage plans, including those administered by United Healthcare, Humana, Highmark, Blue Shield of California, and other national and regional payers
  • Accelerates Coverage and Pricing Efforts: Enables active engagement with MACs to pursue local coverage determinations (LCDs) and supports CMS pricing determinations under the Clinical Laboratory Fee Schedule (CLFS)
  • Medicaid Momentum: Provides essential credentialing for state-by-state Medicaid enrollment



Next Steps: Reimbursement Momentum

With Medicare enrollment secured, CNSide Diagnostics is focused on the following near-term milestones:

  • Medicare Coverage Pathway — Engagement with MACs to secure formal coverage determinations
  • CLFS Pricing — Establishment of a payment rate for the new CPT code 0640U (CNSide CSF TCE Test), effective for billing July 1, 2026, via crosswalk or gapfill methodology
  • Further Commercial Expansion — Continued execution of national and regional payer contracts toward the 2026 goal of 150 million+ covered lives

Positioning CNSide Diagnostics for Scaled Adoption

The CNSide® CSF Assay Platform is a novel diagnostic tool that detects and characterizes tumor cells and circulating tumor DNA in cerebrospinal fluid. It enables earlier and more accurate diagnosis, disease monitoring, and treatment decision-making for patients with leptomeningeal metastases — a devastating complication of CNS cancers where conventional methods like MRI and cytology frequently fall short.

With Medicare enrollment now complete, CNSide Diagnostics is executing a focused commercialization strategy to drive broad clinical adoption:

  • Payer Coverage Expansion: Building on the current 81 million commercial covered lives to further broaden access through additional national and regional payer contracts
  • Clinical Utility & Health Economics: Generating robust real-world data to demonstrate improved patient outcomes and cost-effectiveness
  • Key Account Engagement: Deepening relationships with leading academic medical centers and community oncology networks
  • Reimbursement Optimization: Refining coding, billing, and collections processes to maximize efficiency and revenue capture



About CNSide Diagnostics, LLC

CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. based in Houston, Texas that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases.

About Plus Therapeutics

Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide® CSF Assay, the timing as to when the CNSide® CSF Assay will be commercially launched and expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide® CSF Assay, the development, utility and acceptance of the CNSide® CSF Assay, and expectations as to the Company’s future performance, including development and commercialization of the Company’s product candidates.

Investor Contact

CORE IR
[email protected]



Kelly Reports First-Quarter 2026 Earnings

TROY, Mich., May 07, 2026 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the first quarter of 2026.

  • Q1
    revenue of
    $1.0 billion
    , reflects notable improvement in the year-over-year performance versus the prior quarter driven by strength in the ETM segment,
    down
    10.7%
    year-over-year; underlying revenue excluding previously disclosed discrete items down approximately 3.3% year-over-year, which improved 60 basis points versus the prior quarter
  • Q1
    adjusted SG&A decline of
    10.3%
    reflects the third straight quarter of year-over-year reduction of approximately 10% or more and continued momentum on structural and demand-driven expense optimization initiatives
  • Q1
    operating loss of
    $5.1 million
    ;
    $4.1 million
    of operating earnings on an adjusted basis
  • Q1
    adjusted EBITDA of
    $15.8 million
    and adjusted EBITDA margin of
    1.5%
    reflects a 20 basis point improvement in the year-over-year decline relative to the prior quarter
  • Company affirms expectation of improved year-over-year performance for revenue and adjusted EBITDA margin each successive quarter in 2026, and return to organic revenue growth and adjusted EBITDA margin expansion in the second half of 2026

Chris Layden, chief executive officer, said, “In the first quarter, Kelly’s disciplined execution against our growth and efficiency priorities continued to stabilize the business. Revenue exceeded our expectations and adjusted EBITDA was in line with our outlook, driven by sequential improvement in ETM and pockets of growth in SET. With our technology modernization and go-to-market initiatives on track and our pipeline continuing to gain momentum, we remain confident in our ability to deliver revenue growth and margin expansion in the second half of the year.”

Financial Results for the thirteen-week period ended
March 29, 2026
:

Revenue of $1.0 billion, a 10.7% decrease compared to the corresponding quarter of 2025. Discrete impacts associated with the previously disclosed reduced demand for U.S. federal government contractors in the SET segment and from three large commercial customers in the ETM segment totaled approximately 7.4%, resulting in an underlying revenue decline of approximately 3.3%. Favorable performance areas within underlying revenue include improved demand in the ETM segment, including growth in each of the talent solutions specialties, and within the SET segment growth in the Telecom specialty and improved sequential performance in the Science and Engineering specialties. More than offsetting these items are continued lower demand in the other specialties within the SET segment, largely the technology specialty, and a decline in the Education segment driven by delayed contract decisions, elevated weather-related school closures and declines in student enrollment in key markets.

Operating loss of $5.1 million, compared to earnings of $10.8 million reported in the first quarter of 2025. Adjusted earnings1 were $4.1 million in the first quarter of 2026 and $22.1 million in the first quarter of 2025. Adjusted EBITDA1 of $15.8 million, a decrease of 54.7% versus the prior year period. Adjusted EBITDA margin of 1.5%, a decrease of 150 basis points (“bps”) driven primarily by near-term margin pressure in ETM, Education, and SET reflecting lower gross margins and timing of revenue trends, partially offset by volume-related and structural expense management actions including benefits from our acquisition integration and technology modernization efforts.

Income tax benefit of $0.8 million, compared to income tax expense of $1.8 million reported in the first quarter of 2025. On an adjusted basis1, income tax expense of $1.5 million, compared to income tax expense of $4.7 million in the first quarter of 2025.

Loss per share was $0.17 compared to earnings per share of $0.16 in the first quarter of 2025. On an adjusted basis1, earnings per share were $0.03 in the first quarter of 2026 compared to $0.39 per share in the corresponding quarter of 2025.

1 Adjusted measures represent non-GAAP financial measures. Refer to our reconciliation of non-GAAP financial measures to the most closely related GAAP measure included in this document.

Financial Outlook For Fiscal 2026:

The Company’s 2026 financial outlook remains unchanged from the initial view previously disclosed, assumes no material change in the macroeconomic or industry dynamics relative to current trends, and is as follows:

  • Second Quarter of 2026 – Expect year-over-year improvement relative to first quarter, with overall revenue decline of 7% to 9%, which includes at least 100 bps of improvement on an underlying basis excluding discrete customer impacts​. Adjusted EBITDA margin of at least 2.5%, representing approximately 100 bps improvement relative to first quarter and significant reduction in year-over-year decline relative to the past two quarters.
  • Second Half of the Year – Assuming no new material impacts, expect relative improvement in year-over-year performance each successive quarter for both revenue and adjusted EBITDA margin resulting in modest year-over-year revenue growth and measurable adjusted EBITDA margin expansion in the second half of the year.

Quarterly Cash Dividend:

Kelly also reported that on May 5, its board of directors declared a dividend of $0.075 per share. The dividend is payable on June 2, 2026 to stockholders of record as of the close of business on May 18, 2026.

In conjunction with its earnings release, Kelly has published a financial presentation and will host a live webcast of a conference call at 9 a.m. ET on May 7 to review the financial and operation results from the quarter. The presentation and a link to the live webcast will be accessible through the Company’s public website on the Investor Relations page under Events & Presentations. The webcast will be recorded, and a replay will be available within one hour of completion of the event through the same link as the live webcast.

Forward-Looking Statements:

This release contains statements that are forward looking in nature and, accordingly, are subject to risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Kelly’s financial expectations, are forward-looking statements. Factors that could cause actual results to differ materially from those contained in this release include, but are not limited to, (i) changing market and economic conditions, (ii) disruption in the labor market and weakened demand for human capital resulting from technological advances, competitive pressures and pricing, loss of large corporate customers and government contractor requirements, (iii) the impact of laws and regulations (including federal, state and international tax laws), (iv) unexpected changes in claim trends on workers’ compensation, unemployment, disability and medical benefit plans, (v) litigation and other legal liabilities (including tax liabilities) in excess of our estimates, (vi) our ability to achieve our business’s anticipated growth strategies, (vii) our future business development, results of operations and financial condition, (viii) damage to our brands, (ix) dependence on third parties for the execution of critical functions, (x) conducting business in foreign countries, including foreign currency fluctuations, (xi) availability of temporary workers with appropriate skills required by customers, (xii) cyberattacks or other breaches of network or information technology security, and (xiii) other risks, uncertainties and factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release and we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

About Kelly®

Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect approximately 375,000 people with work every year. Our suite of outsourcing and consulting services and solutions ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2025 was $4.3 billion. Learn more at kellyservices.com.

KLYA-FIN


ANALYST & MEDIA CONTACT:
     

Scott Thomas
     

(248) 251-7264
     
[email protected]       

 
KELLY SERVICES, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE 13 WEEKS ENDED MARCH 29, 2026 AND MARCH 30, 2025
(UNAUDITED)
(in millions, except per share data)

    2026     2025   Change % Change

(1)
Revenue from services $ 1,040.7   $ 1,164.9   $ (124.2 ) (10.7)%
Cost of services   844.3     928.4     (84.1 ) (9.1)
Gross profit   196.4     236.5     (40.1 ) (17.0)
Selling, general and administrative expenses   199.3     225.7     (26.4 ) (11.7)
Asset impairment charge   2.2         2.2   NM
Earnings (loss) from operations   (5.1 )   10.8     (15.9 ) NM
Other income (expense), net   (1.6 )   (3.2 )   1.6   50.0
Earnings (loss) before taxes   (6.7 )   7.6     (14.3 ) NM
Income tax expense (benefit)   (0.8 )   1.8     (2.6 ) (144.4)
Net earnings (loss) $ (5.9 ) $ 5.8     (11.7 ) NM
         
Basic earnings (loss) per share $ (0.17 ) $ 0.16   $ (0.33 ) NM
Diluted earnings (loss) per share $ (0.17 ) $ 0.16   $ (0.33 ) NM
         
STATISTICS:        
Permanent placement income (included in revenue from services) $ 10.9   $ 11.5   $ (0.6 ) (5.2)%
Gross profit rate   18.9 %   20.3 % (1.4) pts.  
Adjusted EBITDA $ 15.8   $ 34.9   $ (19.1 ) (54.7)%
Adjusted EBITDA margin   1.5 %   3.0 % (1.5)pts.  
Effective income tax rate   11.6 %   24.0 % (12.4) pts.  
         
Average shares outstanding:        
Basic   34.4     35.0      
Diluted   34.4     35.5      

(1) Reported percentage changes are computed based on millions. Prior year percent changes were computed based on actual amounts in thousands.

 
KELLY SERVICES, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(in millions)

  March 29, 2026 December 28, 2025 March 30, 2025
Current Assets      
Cash and equivalents $ 25.6   $ 33.0   $ 28.2  
Trade accounts receivable, less allowances of $10.8, $10.0 and $10.6, respectively   1,216.0     1,188.7     1,250.9  
Prepaid expenses and other current assets   57.2     46.6     71.9  
Total current assets   1,298.8     1,268.3     1,351.0  
       
Noncurrent Assets      
Property and equipment, net   18.8     20.5     23.7  
Operating lease right-of-use assets   37.6     42.9     45.9  
Deferred taxes   158.2     163.2     331.1  
Retirement plan assets   283.0     289.7     253.8  
Goodwill, net   202.1     202.1     304.1  
Intangibles, net   218.8     226.2     248.4  
Other assets   37.7     37.7     36.9  
Total noncurrent assets   956.2     982.3     1,243.9  
Total Assets $ 2,255.0   $ 2,250.6   $ 2,594.9  
       
Current Liabilities      
Accounts payable and accrued liabilities $ 621.6   $ 631.4   $ 597.0  
Operating lease liabilities   11.4     12.3     12.2  
Accrued payroll and related taxes   147.2     140.9     178.7  
Accrued workers’ compensation and other claims   21.3     20.9     18.0  
Income and other taxes   17.1     16.3     17.0  
Total current liabilities   818.6     821.8     822.9  
       
Noncurrent Liabilities      
Long-term debt   130.5     101.9     204.6  
Operating lease liabilities   42.0     44.9     49.3  
Accrued workers’ compensation and other claims   34.7     34.2     32.0  
Accrued retirement benefits   253.6     263.7     236.4  
Other long-term liabilities   7.1     7.6     9.2  
Total noncurrent liabilities   467.9     452.3     531.5  
Commitments and contingencies (see Contingencies footnote)      
       
Stockholders’ Equity      
Common Stock   38.5     38.5     38.5  
Treasury Stock   (56.7 )   (63.7 )   (56.1 )
Paid-in capital   31.1     36.3     30.5  
Earnings invested in the business   956.5     965.1     1,233.2  
Accumulated other comprehensive income (loss)   (0.9 )   0.3     (5.6 )
Total stockholders’ equity   968.5     976.5     1,240.5  
Total Liabilities and Stockholders’ Equity $ 2,255.0   $ 2,250.6   $ 2,594.9  
       
STATISTICS:      
Working Capital $ 480.2   $ 446.5   $ 528.1  
Current Ratio   1.6     1.5     1.6  
Debt-to-capital %   11.9 %   9.4 %   14.2 %
Global Days Sales Outstanding   64     61     61  
Year-to-Date Free Cash Flow $ (26.5 ) $ 114.1   $ 21.4  

 
KELLY SERVICES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE 13 WEEKS ENDED MARCH 29, 2026 AND MARCH 30, 2025
(UNAUDITED)
(in millions)

    2026     2025  
Cash flows from operating activities:    
Net earnings (loss) $ (5.9 ) $ 5.8  
Adjustments to reconcile net earnings to net cash from operating activities:    
Asset impairment charge   2.2      
Deferred income taxes   5.0     (0.8 )
Depreciation and amortization   9.9     11.0  
Operating lease asset amortization   2.6     2.6  
Provision for credit losses and sales allowances   1.2     3.0  
Stock-based compensation   3.4     3.7  
Other, net   0.3     (0.3 )
Changes in operating assets and liabilities    
Accounts receivable   (26.3 )   10.5  
Other assets   (4.5 )   0.6  
Accounts payable   (7.3 )   (24.2 )
Other liabilities   (6.0 )   12.0  
Net cash (used in) from operating activities   (25.4 )   23.9  
     
Cash flows from investing activities:    
Capital expenditures   (1.1 )   (2.5 )
Proceeds from sale of PersolKelly investment       6.4  
Other investing activities   (0.1 )   (0.7 )
Net cash (used in) from investing activities   (1.2 )   3.2  
     
Cash flows from financing activities:    
Proceeds from long-term debt   389.5     412.3  
Payments on long-term debt   (360.9 )   (447.1 )
Dividend payments   (2.7 )   (2.8 )
Payments of tax withholding for stock awards   (1.4 )   (1.8 )
Other financing activities   (0.3 )   (0.1 )
Net cash from (used in) financing activities   24.2     (39.5 )
Effect of exchange rates on cash, cash equivalents and restricted cash   (5.8 )   1.3  
Net change in cash, cash equivalents and restricted cash   (8.2 )   (11.1 )
Cash, cash equivalents and restricted cash at beginning of period   37.7     45.6  
Cash, cash equivalents and restricted cash at end of period $ 29.5   $ 34.5  

 
KELLY SERVICES, INC.
SEGMENT INFORMATION
(UNAUDITED)
(in millions)
       
We utilize business unit profit (loss) to evaluate the performance of our segments. Business unit profit (loss) and SG&A expenses as presented in the segment information table below do not include depreciation and amortization expenses.
       
  First Quarter
    2026     2025   % Change
Enterprise Talent Management      
Revenue from services $ 459.2   $ 529.1   (13.2)%
Gross profit   85.6     107.3   (20.2)
Adjusted SG&A expenses   86.9     98.3   (11.6)
Integration, realignment and restructuring charges(2)       2.7   NM
Total SG&A expenses   86.9     101.0   (14.0)
Business unit profit (loss)   (1.3 )   6.3   NM
Adjusted business unit profit (loss)   (1.3 )   9.0   NM
Gross profit rate   18.6 %   20.3 % (1.7) pts.
       
Science, Engineering & Technology      
Revenue from services $ 289.2   $ 327.3   (11.6)%
Gross profit   71.8     83.0   (13.5)
Adjusted SG&A expenses   57.3     68.0   (15.7)
Integration, realignment and restructuring charges(2)   0.3     1.1   (72.7)
Total SG&A expenses   57.6     69.1   (16.6)
Asset impairment charge(5)   2.2       NM
Business unit profit (loss)   12.0     13.9   (13.7)
Adjusted business unit profit (loss)   14.5     15.0   (3.3)
Gross profit rate   24.8 %   25.4 % (0.6) pts.
       
Education      
Revenue from services $ 294.1   $ 309.0   (4.8)%
Gross profit   39.0     46.2   (15.6)
Adjusted SG&A expenses   26.6     26.9   (1.1)
Integration, realignment and restructuring charges(2)   0.1       NM
Total SG&A expenses   26.7     26.9   (0.7)
Business unit profit (loss)   12.3     19.3   (36.3)
Adjusted business unit profit (loss)   12.4     19.3   (35.8)
Gross profit rate   13.3 %   15.0 % (1.7) pts.

 
KELLY SERVICES, INC.
REVENUE FROM SERVICES BY SERVICE TYPE
(UNAUDITED)
(in millions)
           
  First Quarter 2026
  Staffing Services Outcome-based Services Talent Solutions Permanent Placement Total
Enterprise Talent Management $ 229.3 $ 106.8 $ 121.3 $ 1.8 $ 459.2  
Science, Engineering & Technology   168.6   112.2     8.4   289.2  
Education   293.4       0.7   294.1  
Total Segment Revenue $ 691.3 $ 219.0 $ 121.3 $ 10.9 $ 1,042.5  
Intersegment           (1.8 )
Total Revenue from Services         $ 1,040.7  

           
  First Quarter 2025
  Staffing Services Outcome-based Services Talent Solutions Permanent Placement Total
Enterprise Talent Management $ 275.8 $ 133.2 $ 117.8 $ 2.3 $ 529.1  
Science, Engineering & Technology   209.8   109.4     8.1   327.3  
Education   307.9       1.1   309.0  
Total Segment Revenue $ 793.5 $ 242.6 $ 117.8 $ 11.5 $ 1,165.4  
Intersegment           (0.5 )
Total Revenue from Services         $ 1,164.9  

 
KELLY SERVICES, INC.
RECONCILIATION OF NON-GAAP MEASURES
(UNAUDITED)
(in millions, except per share data)
     
  First Quarter
Adjusted SG&A Expenses:   2026     2025  
As reported $ 199.3   $ 225.7  
Integration, realignment and restructuring charges(2)   (4.7 )   (10.7 )
Transaction costs(3)   (0.8 )   (0.3 )
Executive transition costs(4)   (1.5 )   (0.3 )
Adjusted SG&A expenses $ 192.3   $ 214.4  

  First Quarter
Adjusted earnings (loss) from operations:   2026     2025
As reported $ (5.1 ) $ 10.8
Integration, realignment and restructuring charges(2)   4.7     10.7
Transaction costs(3)   0.8     0.3
Executive transition costs(4)   1.5     0.3
Asset impairment charge(5)   2.2    
Adjusted earnings from operations $ 4.1   $ 22.1

  First Quarter
Adjusted income tax expense (benefit):   2026     2025
Income tax expense (benefit) $ (0.8 ) $ 1.8
Taxes on integration, realignment and restructuring charges(2)   1.2     2.7
Taxes on transaction costs(3)   0.2     0.1
Taxes on executive transition costs(4)   0.4     0.1
Taxes on asset impairment charge(5)   0.5    
Adjusted income tax expense (benefit) $ 1.5   $ 4.7

  First Quarter
Adjusted net earnings and earnings per share:   2026     2025
Net earnings (loss) $ (5.9 ) $ 5.8
Integration, realignment and restructuring charges, net of taxes(2)   3.5     8.0
Transaction costs, net of taxes(3)   0.6     0.3
Executive transition costs, net of taxes(4)   1.1     0.2
Asset impairment charge, net of taxes(5)   1.7    
Adjusted net earnings $ 1.0   $ 14.3
     
Diluted earnings (loss) per share $ (0.17 ) $ 0.16
Adjusted diluted earnings per share $ 0.03   $ 0.39

Note: Earnings per share amounts for each quarter are required to be computed independently and may not equal the amounts computed for the total year. Adjusted diluted earnings per share reflects the impact of potentially dilutive securities.

 
KELLY SERVICES, INC.
RECONCILIATION OF NON-GAAP MEASURES
(UNAUDITED)
(in millions)
     
  First Quarter
Total Adjusted EBITDA:   2026     2025  
Net earnings (loss) $ (5.9 ) $ 5.8  
Other (income) expense, net   1.6     3.1  
Income tax expense (benefit)   (0.8 )   1.8  
Depreciation and amortization(1)   11.7     12.8  
EBITDA   6.6     23.5  
Integration, realignment and restructuring charges(2)   4.7     10.7  
Transaction costs(3)   0.8     0.4  
Executive transition costs(4)   1.5     0.3  
Asset impairment charge(5)   2.2      
Adjusted EBITDA $ 15.8   $ 34.9  
Adjusted EBITDA margin   1.5 %   3.0 %

  First Quarter 2026
Business Unit Adjusted EBITDA: Enterprise Talent Management Science, Engineering & Technology Education
Business unit profit (loss) $ (1.3 ) $ 12.0   $ 12.3  
Integration, realignment and restructuring charges(2)       0.3     0.1  
Asset impairment charge(5)       2.2      
Adjusted EBITDA $ (1.3 ) $ 14.5   $ 12.4  
Adjusted EBITDA margin (0.3)%   5.0 %   4.2 %
       
  First Quarter 2025
  Enterprise Talent Management Science, Engineering & Technology Education
Business unit profit (loss) $ 6.3   $ 13.9   $ 19.3  
Integration, realignment and restructuring charges(2)   2.7     1.1      
Adjusted EBITDA $ 9.0   $ 15.0   $ 19.3  
Adjusted EBITDA margin   1.7 %   4.6 %   6.2 %

  First Quarter
Free cash flows:   2026     2025  
Net cash (used in) from operating activities $ (25.4 ) $ 23.9  
Capital expenditures   (1.1 )   (2.5 )
Free Cash Flow $ (26.5 ) $ 21.4  



KELLY SERVICES, INC.

RECONCILIATION OF NON-GAAP MEASURES

(UNAUDITED)

Management uses adjusted EBITDA (adjusted earnings before interest, taxes, depreciation and amortization) and adjusted EBITDA Margin (percent of total GAAP revenue) which Management believes is useful to compare operating performance compared to prior periods and uses it in conjunction with GAAP measures to assess performance. Our calculation of adjusted EBITDA may not be consistent with similarly titled measures of other companies and should be used in conjunction with GAAP measurements. Management also uses year-to-date free cash flow (operating cash flows less capital expenditures) to indicate the change in cash balances arising from operating activities, net of working capital needs and expenditures on fixed assets.

Management believes that the non-GAAP (U.S. Generally Accepted Accounting Principles) information excluding items such as integration, realignment and restructuring charges, transaction costs, executive transition costs and asset impairment charges are useful to understand the Company’s fiscal 2026 financial performance and increases comparability. Specifically, Management believes that removing the impact of these items allows for a meaningful comparison of current period operating performance with the operating results of prior periods. Management also believes that such measures are used by those analyzing performance of companies in the staffing industry to compare current performance to prior periods and to assess future performance.

These non-GAAP measures may have limitations as analytical tools because they exclude items which can have a material impact on cash flow and earnings per share. As a result, Management considers these measures, along with reported results, when it reviews and evaluates the Company’s financial performance. Management believes that these measures provide greater transparency to investors and provide insight into how Management is evaluating the Company’s financial performance. Non-GAAP measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

(1) Represents total company depreciation and amortization of intangibles, including the amortization of hosted software.

(2) Integration, realignment and restructuring charges in the first quarter 2026 and 2025 reflect various initiatives aimed at integrating MRP and other prior acquisitions and further aligning processes and technology across the Company. The costs incurred associated with these initiatives are summarized in the table below:

  First Quarter
    2026   2025
IT-related charges $ 3.5 $ 5.3
Severance   0.3   4.4
Fees and other costs   0.9   1.0
Total integration and realignment costs $ 4.7 $ 10.7
         

(3) Transaction costs in 2026 primarily related to costs incurred in connection with our controlling shareholder change in the first quarter of 2026. Transaction costs in 2025 include costs incurred directly related to the sale of the EMEA staffing operations, which includes employee termination costs and transition costs.

(4) Executive transition costs in 2026 represent non-recurring expenses primarily associated with our segment leader changes in 2025 and 2026. Executive transition costs in 2025 represent expenses associated with our CEO transition in 2025.

(5) Asset impairment charge in 2026 relates to certain right-of-use assets and reflects the Company’s ongoing realignment of our lease portfolio.



Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global Healthcare Conference, being held May 12-14 in Las Vegas, Nevada. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on May 12 at 10:00am PT.

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:

Jacob Johnson
VP, Investor Relations
781-419-0204
[email protected]